Compositions and methods comprising protease-activating therapeutic agents

By exposing the peptide masking agent technology in the tumor microenvironment, combined with the collagen binding domain, the problem of IL-12 toxicity was solved, and cytokines were effectively activated in the tumor, reducing the therapeutic toxicity and improving the anti-tumor effect.

CN114466657BActive Publication Date: 2024-11-15UNIVERSITY OF CHICAGO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080067433.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-25
Filing Date
2020-07-24
Publication Date
2024-11-15
Estimated Expiration
2040-07-24

AI Technical Summary

Technical Problem

Interleukin-12 (IL-12) as a cytokine has shown anti-tumor effects in cancer immunotherapy, but due to its severe toxicity, some clinical trials have been terminated or failed, and the prior art is difficult to effectively reduce its therapeutic toxicity.

Method used

By designing masking agents containing tumor-associated protease cleavage sites, collagen binding modification engineering is used to expose therapeutic agents to the tumor microenvironment, reducing off-target side effects and toxicity related to systemic administration, using polypeptide technology to fuse cytokines with their receptors to form Procytokines activated in tumors reduce immunotoxicity.

Benefits of technology

It effectively reduces the toxicity of IL-12, retains its therapeutic effect, and improves anti-tumor efficacy through the design of tumor targeting agents, reducing damage to healthy tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003563111360000071
    Figure BDA0003563111360000071
  • Figure BDA0003563111360000081
    Figure BDA0003563111360000081
  • Figure BDA0003563111360000082
    Figure BDA0003563111360000082
Patent Text Reader

Abstract

The present disclosure relates to engineering of collagen-bound modifications of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which exposes the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Therefore, aspects of the present disclosure relate to polypeptides comprising a therapeutic agent bound to a masking agent via a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the connection of the therapeutic agent to its therapeutic target, and wherein the polypeptide is operably bound to a collagen binding domain or a tumor targeting agent.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 878,574, filed on July 25, 2019, the contents of which are incorporated herein by reference in their entirety. Background Art

[0003] Cytokine cancer immunotherapy using interleukin (IL)-12 has shown strong anti-tumor effects in both mice and humans. However, due to its severe toxicity, some IL12 clinical trials have been terminated or failed. IL12 has not yet been approved for clinical use. Immunotherapy is used to activate immune responses, and for this reason, side effects usually come from drug effects in healthy organs. Strategies to reduce therapeutic toxicity are needed in the art. Summary of the invention

[0004] The present disclosure relates to engineering of collagen-bound modifications of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which exposes the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Therefore, aspects of the present disclosure relate to polypeptides comprising a therapeutic agent bound to a masking agent via a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the connection of the therapeutic agent to its therapeutic target, and wherein the polypeptide is operably bound to a collagen binding domain or a tumor targeting agent.

[0005] Other aspects of the present disclosure relate to polypeptides comprising cytokines connected to a masking agent via a linker, wherein the linker comprises one or more than one tumor-associated protease cleavage site, and wherein the masking agent comprises a cytokine receptor polypeptide or fragment thereof that specifically binds to the cytokine. A masking agent refers to a molecule that blocks the binding of a therapeutic agent to at least one binding partner. In some embodiments, the therapeutic agent comprises an antibody, and the binding partner comprises an antigen. In some embodiments, the therapeutic agent comprises a cytokine, and the binding partner comprises a binding receptor polypeptide.

[0006] Other aspects relate to compositions comprising the polypeptides of the present disclosure. Additional aspects relate to nucleic acids encoding the polypeptides of the present disclosure and host cells comprising the nucleic acids and / or polypeptides of the present disclosure. Methods for preparing the polypeptides are also provided, comprising expressing the nucleic acids of the present disclosure in a host cell and isolating the expressed polypeptides. Other aspects relate to methods for treating cancer, comprising administering the polypeptides or compositions of the present disclosure to a subject in need thereof, such as a subject suffering from cancer.

[0007] In some embodiments, the cytokine comprises interleukin-12 (IL12), and wherein the masking agent comprises an interleukin 12 receptor (IL12R) polypeptide or an IL12 binding fragment thereof. In some embodiments, IL12 comprises one or both of the p35 and p40 subunits. In some embodiments, IL12 comprises p35 and p40 subunits connected by disulfide bonds. In some embodiments, IL12 comprises p35 and p40 subunits connected by peptide linkers. In some embodiments, the IL12R polypeptide or fragment comprises interleukin 12 receptor β1 (IL12Rβ1) or a fragment thereof. In some embodiments, the IL12R polypeptide or fragment comprises interleukin 12 receptor β2 (IL12Rβ2) or a fragment thereof. In some embodiments, the IL12Rβ1 polypeptide comprises one or both of the fibronectin domains D1 and D2.

[0008] In some embodiments, the masking agent is fused to the N-terminal of the p35 subunit of IL12, and the joint comprising a tumor-related protease cleavage site is located between the masking agent and the p35 subunit of IL12. In some embodiments, the masking agent is fused to the C-terminal of the p35 subunit of IL12, and the joint comprising a tumor-related protease cleavage site is located between the masking agent and the p35 subunit of IL12. In some embodiments, the masking agent is fused to the C-terminal of the p40 subunit of IL12, and the joint is located between the masking agent and the p40 subunit of IL12. In some embodiments, the masking agent is fused to the N-terminal of the p40 subunit of IL12, and the joint is located between the masking agent and the p40 subunit of IL12. In some embodiments, the cytokine comprises interleukin-2 (IL-2), and the masking agent comprises interleukin 2 receptor alpha subunit (IL-2Rα), interleukin 2 receptor beta subunit (IL-2Rβ), interleukin 2 receptor gamma subunit (IL-2Rγ), a fragment or a combination of its fragments. In some embodiments, the cytokine comprises interferon gamma (IFNγ), and the masking agent comprises interferon gamma receptor 1 (IFNγR1), interferon gamma receptor 2 (IFNγR2), a fragment or a combination of its fragments.

[0009] In some embodiments, the polypeptide comprises at least two tumor-associated protease cleavage sites. In some embodiments, the polypeptide comprises at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, or 8 tumor-associated protease cleavage sites, or any range derivable therein. In some embodiments, the tumor-associated protease cleavage site comprises uPA, matrix metalloproteinase, or thrombin cleavage site. In some embodiments, the tumor-associated protease cleavage site comprises at least one tumor-associated protease cleavage site described herein. In some embodiments, the tumor-associated protease cleavage site comprises a cleavage site having an amino acid of one of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 55, SEQ ID NO: 109 to SEQ ID NO: 190. In some embodiments, the polypeptide comprises at least two different tumor-associated protease cleavage sites. In some embodiments, the polypeptide comprises at least 2, 3, or 4 different tumor-associated protease cleavage sites, or any range derivable therein. In some embodiments, the polypeptide comprises at least 2 identical tumor-associated protease cleavage sites. In some embodiments, the polypeptide comprises at least 2, 3, 4, 5, 6, 7, or 8 identical protease cleavage sites, or any range derivable therein. In embodiments comprising more than one protease cleavage site, the protease cleavage site may be adjacent or have inserted amino acids. In some embodiments, at least, at most, or exactly 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids, or any range derivable therein, separate one tumor-associated protease cleavage site from another tumor-associated protease cleavage site.

[0010] In some embodiments, the cytokines include anti-inflammatory cytokines. In some embodiments, the cytokines include pro-inflammatory cytokines.

[0011] In some embodiments, the polypeptide is conjugated to a tumor targeting agent. In some embodiments, the tumor targeting agent includes an antibody or an antigen binding fragment thereof. In some embodiments, the antibody or antigen binding fragment includes a matrix-targeted antibody or a matrix-binding fragment thereof. In some embodiments, the antibody or binding fragment specifically binds to fibronectin, an alternative splicing domain of fibronectin, collagen, tenascin, periostin, syndecan, proteoglycan, or a tumor stromal cell-specific antigen. In some embodiments, the antibody or binding fragment specifically binds to an extra domain A (EDA) or an extra domain B (EDB) of fibronectin. In some embodiments, the tumor targeting agent includes a Fab that specifically binds to an alternative splicing domain of fibronectin comprising an extra domain A (EDA). In some embodiments, the tumor targeting agent comprises an antibody or antigen binding fragment that specifically binds to a tumor-associated antigen. Other tumor targeting agents include those listed in US20140294723A1, WO2001062298A2, WO1997045544A1, WO2006119897A2, WO2006050834A2, WO2008120101A2, WO2010078916A1, which are incorporated herein by reference.

[0012] In some embodiments, the tumor targeting agent comprises a collagen binding domain. In some embodiments, the polypeptide comprises at least two collagen binding domains. In some embodiments, the polypeptide comprises at least 2, 3, 4, 5, or 6 collagen binding domains. In some embodiments, the polypeptide comprises a collagen binding domain from decorin or von Willebrand Factor (VWF).

[0013] In some embodiments, the polypeptide further comprises a serum protein conjugated to the polypeptide. In some embodiments, the serum protein is conjugated to the polypeptide via a peptide bond. In some embodiments, the serum protein comprises albumin or a fragment thereof. In some embodiments, the serum protein is at least 40 kDa, 45 kDa, 50 kDa, 55 kDa, 60 kDa, 65 kDa, 70 kDa, or 75 kDa (or any range derivable therein).

[0014] In some embodiments, the polypeptide comprises a second linker. In some embodiments, the second linker comprises glycine and serine amino acid residues. In some embodiments, the polypeptide comprises a third, fourth, or fifth linker. In some embodiments, the third, fourth, or fifth linker comprises glycine and serine amino acid residues. In some embodiments, the linker comprises (GGGS) n(SEQ ID No: 48), wherein n = 1, 2, 3, 4, 5, 6, 7 or 8, or any range derivable therein, or GGGSGGGS (SEQ ID NO: 47). In some embodiments, the second linker comprises (GGGS) n (SEQ ID NO:48), wherein n=6. In some embodiments, the polypeptide comprises a protein tag. In some embodiments, the protein tag comprises a 6H tag. In some embodiments, the protein tag comprises a protein tag described herein. In some embodiments, the polypeptide is not operably linked to a particle, nanovesicle, or liposome. In some embodiments, the composition does not comprise a liposome, a particle, or a nanovesicle.

[0015] In some embodiments, the method or the disclosure relates to the treatment of skin cancer, such as the treatment of melanoma. In some embodiments, the method of the present disclosure further comprises administering one or more than one additional cancer therapy. In some embodiments, the additional therapy is one described herein. In some embodiments, the subject has or will receive immunotherapy. In some embodiments, the method further comprises administering immunotherapy. In a specific embodiment, immunotherapy includes an immune checkpoint inhibitor. The immune checkpoint inhibitor can be an anti-PD-1 monoclonal antibody or an anti-CTLA-4 monoclonal antibody. Other exemplary immune checkpoint proteins that can be inhibited in the embodiments of the present disclosure are described herein. In some embodiments, the immune checkpoint inhibitor includes one or more than one of nivolumab, pembrolizumab, pidilizumab, ipilimumab, or tremelimumab. In some embodiments, immune checkpoint therapy is a monotherapy. The term monotherapy, in the context of immune checkpoint therapy, refers to the administration of an immune checkpoint inhibitor during treatment. Monotherapy can be a therapy comprising only one of PD-1, PDL1, PDL2, CTLA-4, B7-1 or B7-2 inhibitors. In some embodiments, immune checkpoint inhibitor therapy includes a combination therapy. For example, a combination therapy can be a combination of (i) PD-1, PDL1 or PDL2 inhibitors and (ii) CTLA-4, B7-1 or B7-2 inhibitors. Specific combination therapy includes those comprising anti-PD-1 antibodies and anti-CTLA-4 antibodies. Other immunotherapies that can be used for the methods and compositions of the present disclosure are described herein. In some embodiments, immunotherapy or another therapy is administered before, after or simultaneously with the polypeptide. In some embodiments, the polypeptide or composition is administered systemically. In some embodiments, the polypeptide or composition is administered by a route of administration as described herein. In some embodiments, the polypeptide or composition is administered by intravenous injection. In some embodiments, the subject has previously been treated with cancer therapy. In some embodiments, it has been determined that the subject has no response to a previous treatment, or wherein the subject has experienced nonspecific toxicity to a previous treatment.

[0016] As used herein, the term "cytokine polypeptide" refers to a polypeptide that is a cytokine or its receptor binding domain and retains a portion of the cytokine activity.

[0017] The terms "protein," "polypeptide," and "peptide" are used interchangeably herein when referring to a gene product comprising a polymer of amino acids.

[0018] The terms "subject," "mammal," and "patient" are used interchangeably. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a mouse, rat, rabbit, dog, donkey, or a laboratory test animal, such as a fruit fly, zebrafish, etc.

[0019] It is contemplated that the methods and compositions include and exclude any embodiments described herein.

[0020] As used herein, the terms "or" and "and / or" are used to describe multiple components that are combined with each other or mutually exclusive. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z", "(x and y) or z", "x or (y and z)", or "x or y or z". It is specifically contemplated that x, y, or z can be specifically excluded from an embodiment.

[0021] In this application, the term "about" is used according to its ordinary and customary meaning in the art of cell biology to indicate a value that includes the standard deviation of error for the device and or method being employed to determine the value.

[0022] The term "comprising," which is synonymous with "including," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. The phrase "consisting of" excludes any unspecified elements, steps, or ingredients. The phrase "consisting essentially of" limits the scope of the subject matter to the specified materials or steps and those that do not materially affect the basic and novel characteristics thereof. It is contemplated that embodiments described in the context of the term "comprising" may also be implemented in the context of the terms "consisting of" or "consisting essentially of."

[0023] It is specifically contemplated that any limitation discussed with respect to one embodiment of the invention may apply to any other embodiment of the invention. In addition, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or utilize any composition of the invention. Aspects of the embodiments described in the examples are also embodiments that may be implemented in the context of embodiments discussed elsewhere in different embodiments or elsewhere in this application, such as the Summary of the Invention, the Detailed Description of the Invention, the Claims, and the Description of the Figures. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the present invention. The present invention may be better understood by referring to one or more of these drawings in conjunction with the detailed description of specific embodiments presented herein.

[0025] Figures 1A to 1CSchematic diagram of IL12Rβ1 recombinant protein fused to IL12. (A) Schematic diagram of IL12Rβ1 recombinant protein fused to IL12. The IL12Rβ1-IL12 receptor binding site is not exposed in peripheral tissues, but tumor-specific proteases expose the IL12 binding site in tumors. (B to C) Structure of IL12Rβ1 fibronectin I and II domains fused to IL12.

[0026] Figure 2A-2B. Fusion of IL12Rβ1 fibronectin I and II domains to IL12 inactivates IL12 activity in vitro and in vivo. (A) IFNγ concentrations after in vitro culture of splenocytes. IFNγ concentrations in supernatants were measured by ELISA after 2 days of culture in the presence of IL12. (B) 5×10 5 B16F10 cells. IL12 variants (25 μg, based on IL12) were injected intravenously on day 7. On day 9, blood was collected and IFNγ concentration in serum was determined by ELISA.

[0027] Figure 3A to Figure 3P. IL12Rβ1 fusion reduces potential therapeutically relevant toxicity of IL12. (A) In vitro cleavage of IL12Rβ1-VP-IL12 and IL12Rβ1-LS-IL12 by MMP and uPA. IL-12, IL12Rβ1-VP-IL12, and IL12Rβ1-LS-IL12 were treated with assay buffer alone (blank), MMP2, MMP9, or uPA for 30 minutes at 37°C. The decrease in molecular weight from approximately 105 kDa to approximately 60 kDa indicates proteolytic cleavage of IL12Rβ1-VP-IL12 and IL12Rβ1-LS-IL12. (B) In vitro activity of IL12Rβ1-VP-IL12, IL12Rβ1-LS-IL12, and IL12Rβ1-(G3S) 11 - Indegradability of IL12. IL-12, IL12Rβ1-VP-IL12, IL12Rβ1-LS-IL12 and IL12Rβ1-(G3S) 11 - IL12 was administered to pre-activated mouse CD8 + T cells and the phosphorylation of STAT4 was assessed by flow cytometry. Dose-response relationships and half-maximal activation values ​​are shown. (C) In vitro activity of IL12Rβ1-VP-IL12, IL12Rβ1-LS-IL12 after protease treatment. IL12Rβ1-VP-IL12 or IL12Rβ1-LS-IL12 were first treated with MMP2 or uPA, respectively. The cleaved constructs or IL-12 were administered to pre-activated mouse CD8 +T cells and the phosphorylation of STAT4 was assessed by flow cytometry. Dose-response relationships and half-maximal activation values ​​are shown. (D) In ​​vivo toxicity of IL12Rβ1-VPLS-IL12-CBD in healthy mice. C57BL / 6 mice were treated with PBS, IL12 or IL12Rβ1-VPLS-IL12-CBD by intravenous injection on days 0, 3 and 6 (doses are expressed as IL12 molar basis). On days 2, 5 and 8, mice were bled and the presence of proinflammatory cytokines in serum was analyzed using the LEGENDplex cytokine release syndrome plate. (E) White blood cell counts and (F) platelet counts were determined by a hematology analyzer. (GN) Hematologic toxicity markers were analyzed after injection of IL12Rβ1-IL12 in non-tumor-bearing mice. Figure depicts analysis of liver injury markers (blood albumin concentration, total protein, alanine aminotransferase (ALT) activity, aspartate aminotransferase (AST) activity, and alkaline phosphatase activity), kidney injury markers (total bilirubin), pancreatic injury markers (amylase), and lung injury markers (CO2 concentration). (OP) Analysis of blood toxicity markers (ALT activity and amylase) after injection of IL12Rβ1-IL12 and anti-PD-1 antibody into B16F10 tumor-bearing mice. Statistical analysis was performed using analysis of variance with Turkey's test. *p<0.05**p<0.01; NS=not significant.

[0028] Figure 4A-4D. Treatment with IL12Rβ1-IL12 with a cleavable linker reduces the growth rate of B16F10 melanoma. 5×10 5 B16F10 cells. IL12 (25 μg), equimolar IL12 variants, or PBS were administered by intravenous injection on (A) day 8 or (B) day 7. (A to B) IL12Rβ1-IL12 with a uPA protease cleavable linker (LS) was used. (C) IL12 (5 μg) and IL12Rβ1-IL12 (50 μg) with uPA and MMP protease cleavable linkers (VP-LS) were injected intravenously every 3 days from day 7. (D) 100 μg of IL12Rβ1-IL12 with cleavable linkers (HP, VP and LS) were injected intravenously on days 7 and 10. Anti-PD-1 antibodies were injected intraperitoneally on days 7, 10 and / or 13. The figure describes the tumor volume until the death of the first mouse. Tumor volume is expressed as mean ± SEM. n = 3-4 DETAILED DESCRIPTION

[0029] Cytokines are key factors in anti-tumor activity, but not many of them have been translated into the clinic so far. IL12 is one of the strongest anti-tumor cytokines, but due to its high toxicity, clinical trials have been terminated or unsuccessful. Therefore, reducing its toxicity is an important strategy for its translation into the clinic. In order to improve CBD-IL12 therapy, the domain of the IL12 receptor IL12Rβ1 is fused with IL12 to form IL12Rβ1-IL12. This fusion is inactive, but the inclusion of MMP or thrombin cleavage sites between the receptor generator and the cytokine will produce pro-cytokines that can be activated in the tumor microenvironment. The inventors have demonstrated that the immunotoxicity of IL12 is therefore reduced, and the fusion of IL12Rβ1-IL12 with a protease-sensitive linker retains the therapeutic effect. The inventors also found that introducing multiple cleavage sites into the linker (e.g., tandem MMP, tandem thrombin and MMP-thrombin dimers and repeats) will increase protease sensitivity and can increase the anti-tumor efficacy of IL12Rβ1-IL12 therapy. In addition, the use of collagen binding domains fused to the masked therapeutic molecules of the present disclosure is particularly useful because the CBD increases the retention of the masked therapeutic in the tumor microenvironment, which prolongs the exposure of the masked therapeutic to proteases and increases the local concentration of the unmasked therapeutic. In summary, the inventors have developed a technology to reduce the toxicity of therapeutics by fusing cytokine receptors to cytokines. Tumor-specific proteases cleave the linker to activate the cytokines within the tumor.

[0030] I. Polypeptide Embodiments

[0031] A. Therapeutic and Masking Agents

[0032] Embodiments of the present disclosure relate to therapeutic agents and masking agents that bind to the therapeutic agents and prevent the therapeutic agents from binding to their targets to reduce toxicity associated with the therapeutic agents. The polypeptides of the present disclosure contain tumor-associated protease cleavage sites that do not mask the therapeutic agents when they encounter the associated protease. Since proteases are enriched in the tumor microenvironment, when systemically administered, active therapeutic agents are reduced in normal tissues compared to systemic administration of non-masked therapeutic agents.

[0033] 1. Cytokines

[0034] In some embodiments, the therapeutic agent comprises a cytokine or a therapeutic polypeptide from a cytokine. In certain embodiments, the cytokine comprises a functionally active fragment of a cytokine. In certain embodiments, the functionally active cytokine fragment binds to and activates a corresponding receptor. In some embodiments, the cytokine comprises IL12. IL12 is a heterodimeric glycosylated cytokine consisting of a p35 (~35 kDa) and a p40 (~40 kDa) subunit linked by a disulfide bond. The human IL12 p35 sequence is represented by:

[0035] The human IL12 p40 sequence is represented by:

[0036]

[0037] The mouse IL12 p35 sequence is represented by:

[0038] The mouse IL12 p40 sequence is represented by:

[0039]

[0040] Suitable IL12 masking agents include polypeptides that bind to IL12 and prevent IL12 from binding to other molecules, such as IL12R. Exemplary polypeptides include polypeptides from IL12R, such as IL12Rβ1 and IL12Rβ2.

[0041] Mouse IL12Rβ1 is represented by a polypeptide having any of the following amino acid sequences:

[0042]

[0043] Human IL12Rβ1 is represented by a polypeptide having the following amino acid sequence:

[0044]

[0045] Human IL12Rβ2 is represented by a polypeptide having the following amino acid sequence:

[0046]

[0047] Mouse IL12Rβ2 is represented by a polypeptide having the following amino acid sequence:

[0048]

[0049] In some embodiments, the cytokine includes a polypeptide comprising the amino acid sequence of SEQ ID NO:3 to SEQ ID NO:6, or a polypeptide comprising the amino acid sequence of a polypeptide fragment represented by SEQ ID NO:3 to SEQ ID NO:6, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with a polypeptide of SEQ ID NO:3 to SEQ ID NO:6 or a fragment thereof.

[0050] In some embodiments, the cytokine comprises an IL12 polypeptide and the masking agent comprises an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 19 to SEQ ID NO: 22, or a polypeptide comprising an amino acid sequence of a polypeptide fragment represented by SEQ ID NO: 2 or SEQ ID NO: 19 to SEQ ID NO: 22, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with a polypeptide of SEQ ID NO: 2 or SEQ ID NO: 19 to SEQ ID NO: 22 or a fragment thereof.

[0051] In some embodiments, the cytokine comprises IL-2. Human IL-2 sequences include Mouse IL-2 sequences include

[0052] In some embodiments, the masking agent for IL-2 includes an IL-2R polypeptide. In some embodiments, the IL-2R polypeptide includes a polypeptide from an IL-2Rβ, IL-2Rα, or IL-2Rγ subunit. Human interleukin-2 receptor subunit β comprises the following amino acid sequence:

[0053]

[0054] Mouse interleukin-2 receptor subunit beta has the following amino acid sequence:

[0055] Human interleukin-2 receptor subunit alpha has the following amino acid sequence:

[0056]

[0057] Mouse interleukin-2 receptor subunit alpha has the following amino acid sequence:

[0058] Human interleukin-2 receptor subunit gamma has the following amino acid sequence:

[0059] Mouse interleukin-2 receptor subunit gamma has the following amino acid sequence:

[0060]

[0061] In some embodiments, the cytokine includes a polypeptide comprising the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:24, or a polypeptide comprising the amino acid sequence of a polypeptide fragment represented by SEQ ID NO:23 and SEQ ID NO:24, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with the polypeptide of SEQ ID NO:23 or SEQ ID NO:24 or a fragment thereof.

[0062] In some embodiments, the cytokine comprises an IL-2 polypeptide and the masking agent comprises an amino acid sequence of SEQ ID NO: 27 to SEQ ID NO: 32, or a polypeptide comprising an amino acid sequence of a polypeptide fragment represented by SEQ ID NO: 27 to SEQ ID NO: 32, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with a polypeptide of SEQ ID NO: 27 to SEQ ID NO: 32 or a fragment thereof.

[0063] In some embodiments, the cytokine comprises IFNγ. Mouse IFNγ comprises the following sequence:

[0064] Human IFNγ includes the following sequence:

[0065]

[0066] IFNγ can be a functional fragment, such as a fragment truncated at the C-terminus. For example, the IFNγ polypeptide can be a polypeptide comprising at least 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 124, 125, 126, 127, 128, 129, 130, 131, or 132 SEQ. A polypeptide comprising consecutive amino acids of SEQ ID NO:25 or SEQ ID NO:26.In some embodiments, the IFNy polypeptide may be a polypeptide comprising at least 1 to 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 124, 125, 126, 127, 128, 129, 130, 131, or 132 (or any range derivable therein) SEQ. A polypeptide having the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:26.

[0067] In some embodiments, the masking agent for the IFNγ polypeptide comprises a polypeptide from IFNγ receptor 1 or IFNγ receptor 2. Human IFNγ receptor 1 comprises the following sequence:

[0068]

[0069] Mouse IFNγ receptor 1 includes the following sequence:

[0070]

[0071] Human IFNγ receptor 2 includes the following sequence:

[0072]

[0073] Mouse IFNγ receptor 2 includes the following sequence:

[0074]

[0075] In some embodiments, the cytokine includes a polypeptide comprising the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:26, or a polypeptide comprising the amino acid sequence of a polypeptide fragment represented by SEQ ID NO:25 and SEQ ID NO:26, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with the polypeptide of SEQ ID NO:25 or SEQ ID NO:26 or a fragment thereof.

[0076] In some embodiments, the cytokine comprises an IFNy polypeptide and the masking agent comprises an amino acid sequence of SEQ ID NO:33 to SEQ ID NO:36, or a polypeptide comprising an amino acid sequence of a polypeptide fragment represented by SEQ ID NO:33 to SEQ ID NO:36, or a polypeptide having at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity with a polypeptide of SEQ ID NO:33 to SEQ ID NO:36 or a fragment thereof.

[0077] In embodiments of the present disclosure, the prepared masking agent may be a polypeptide or a functional fragment of a polypeptide as described herein. In some embodiments, the masking agent comprises a receptor polypeptide or a fragment thereof that binds to a cytokine.

[0078] 2. Antibodies

[0079] In some embodiments, therapeutic agents include antibodies, such as therapeutic antibodies. In some embodiments, therapeutic antibodies are modified by site-specific replacement of amino acids in the heavy or light chain variable regions with cysteine ​​(Cys). The sulfhydryl (SH) group in the replaced Cys side chain serves as a chemical handle for connecting a masking agent that interferes with the ability of the antibody to bind to its antigen. The masking agent can be a group that spatially inhibits antibody-antigen binding, but otherwise does not interact specifically with the antibody or antigen.

[0080] Alternatively, the masking agent may interact with the antibody, for example, via electrostatic or van der Waals forces.The tumor-associated protease cleavage site may be located between or linking the masking agent and the antibody.

[0081] In some embodiments, the masking agent may have its own pharmacological activity after being released by cleavage of the tumor-associated protease cleavage site. The Cys substitution site is selected so that the replacement of the original amino acid with Cys does not adversely affect the ability of the antibody to bind specifically and strongly to its antigen. Moreover, removal of the masking agent may leave a residual chemical group still covalently attached to the Cys.

[0082] In one embodiment, a prodrug antibody according to formula (I) is provided:

[0083] (ML) m -Ab I

[0084] wherein Ab is an antibody having at least one amino acid replaced by Cys in its heavy chain or light chain variable region, wherein the replaced amino acid (a) is in the framework region; (b) has at least 30% side chain exposure, and (c) is within 10A, preferably 5A of CDR amino acids; M is a masking agent that inhibits the binding of Ab to its antigen; each L is independently a linker portion that is bonded to M and Ab, L comprises a tumor-associated cleavage site and is bonded to Ab at the aforementioned Cys; and m is 1, 2, 3 or 4.

[0085] In some embodiments, at least one substituted amino group in antibody Ab is located at position 1, 3, 5, 19, 23, 25, 43, 46, 68, 72, 74, 75, 76, 82a, 82b, 83, 84, 85, or 105 of the Kabat system of the heavy chain variable region, or at position 1, 3, 5, 7, 8, 18, 20, 45, 57, 60, 63, 65, 66, 67, 69, 77, or 100 of the Kabat system of the light chain variable region. In some embodiments, at least one substituted amino acid in antibody Ab is located at position 23 of the Kabat system of the heavy chain or position 67 of the Kabat system of the light chain. In some embodiments, an antibody is provided that has a Cys at position 67 of the Kabat system of the light chain. The antibody can be an anti-CTLA4 antibody or an anti-CD137 antibody. In some embodiments, an antibody is provided that has a Cys at position 23 of the Kabat system of the heavy chain. The antibody can be an anti-CTLA4 antibody or an anti-CD137 antibody.

[0086] The masked therapeutic antibodies disclosed herein can be polyclonal, monoclonal, mouse, human, humanized or chimeric. Suitable amino acids in the heavy and light chain variable regions for replacement with Cys are framework amino acids whose side chains are exposed to the solvent, preferably at least 30% exposed to the solvent, so that the replaced Cys can be used to connect the masking agent. It is also important that the replaced amino acid is close to the CDR amino acids so that the masking agent can effectively interfere with antibody-antigen binding. Preferably no more than 10A in particular, more preferably no more than 5A. Preferred positions for Cys replacement include position 23 of the heavy chain variable region and position 67 of the light chain variable region, according to Kabat numbering. Both positions are in the framework region of their respective variable regions. Cys can be replaced to these positions by site-specific replacement techniques well known in the art. Replacement at the first position can be referred to using simplified symbols such as V L X67C, where X represents the replaced amino acid. In natural antibodies, this position is highly conserved and is usually Ser. The replacement at the second position can be similarly called V H X23C.

[0087] The masked antibodies of the present disclosure may have substitutions in the VH region or in the VL region or in both. If the antibody has only one of these substitutions, the theoretical maximum number of blocking moiety-linker compounds that can be attached is two, although masked antibody preparations may statistically analyze lower numbers, reflecting chemical inefficiencies in the attachment process. If the antibody has two substitutions, the theoretical maximum number is four.

[0088] In some embodiments, the antibody is a bispecific antibody, which has two pairs of different heavy and light chains. Thus, the masked antibodies of the present disclosure may be bispecific antibodies in which only one heavy / light chain pair is masked or in which both heavy / light chain pairs are masked. It is also known to replace amino acids in the VH or VL region with Cys for the purpose of introducing sulfhydryl side chains that can be conjugated by maleimide addition chemistry for the preparation of antibody-drug conjugates. For example, see Eigenbrot et al. (2007) and Bhakta et al. (2016).

[0089] Masking agents that can be used to interfere with or block the activity of masked antibodies with their antigens include polyethylene glycol (PEG), albumin-binding polypeptides, adnectins, peptides, and soluble globular proteins such as albumin or fibronectin. In some embodiments, the blocking agent includes a PEG having a molecular weight of at least about 2 kDa, wherein 2 kDa corresponds to a PEG having about 45 -(CH2CH2O)- repeating units, and preferably a PEG having a molecular weight of at least about 5 kDa, wherein 5 kDa corresponds to a PEG having about 115 -(CH2CH2O)- repeating units.

[0090] As known in the art, antibodies with Cys as described herein can be conjugated to masking agents with maleimide end groups by Michael addition of Cys sulfhydryl groups. Such conjugation processes are known in the art, see, for example, Shepard et al., WO 2017 / 112624 A1 (2017), which is incorporated herein by reference. Other examples of specific masking agents for therapeutic antibodies are disclosed in WO2019036433, which is incorporated herein by reference.

[0091] In other embodiments, the therapeutic agent may be an antibody in which the variable region is masked by connecting the N-terminus of the variable region chain to a peptide that forms a coiled coil. The peptides that form the coiled coil are linked to each other to form a coiled coil (i.e., each peptide forms a coil each, and these coils are wound around each other). The coiled coil can sterically inhibit the binding of the antibody binding site to its target. In some embodiments, the antibody includes a bivalent antibody. The non-covalent binding between the peptides that form the coiled coil is sufficient to form a stable coiled coil that inhibits the binding of the antibody variable region; for example, the peptides that form the coiled coil do not have to be further connected by a disulfide bond between the terminal cysteines of the corresponding peptides. The presence of non-naturally occurring cysteines may be disadvantageous because they can cause misfolding or mispairing problems. Masking antibodies in this form can reduce binding affinity (and the cytotoxic activity of ADC) to less than one percent. Antibodies can be masked in this form without causing significant damage to expression, purification, conjugation, pharmacokinetics, or binding or other unmasked activities.

[0092] In some embodiments, the masking agent includes a coiled coil. The peptides that form coiled coils are peptide pairs that can bind to each other to form coiled coils. "Coiled coil" is a term in the art and refers to an alpha helical bundle that is wound into a superhelical structure. The peptide that forms a leucine zipper is an example of a peptide that binds to form a coiled coil. The coiled coil formed in the present disclosure is usually formed by two peptides that form coiled coils. The coiled coil can form alpha helices in parallel or opposite directions on the peptide. The coiled coil is further characterized by folding amino acid side chains in the core of the bundle, called knobs-into-holes, in which residues from one helix (knob) are folded into a space surrounded by four side chains of the facing helix (hole). The residues involved in the knobs-into-holes interaction are usually hydrophobic, while the outer residues are hydrophilic, so the sequence of the coiled coil exhibits a "heptapeptide" repeat in the chemical nature of the side chains. Examples of consensus formulas for heptad repeats in coiled-coil forming peptides are provided in WO2011034605, which is incorporated herein by reference.

[0093] In some embodiments, the coiled-coil comprises Formula II:

[0094] (XI, X2, X3, X4, X5, X6, X7)n II

[0095] wherein XI is a hydrophobic amino acid or asparagine; X2, X3 and X6 are any amino acids; X4 is a hydrophobic amino acid; and X5 and X7 are each a charged amino acid residue.

[0096] Examples of coiled coils include: and The peptide forming the coiled coil is connected to the N-terminus of the antibody variable region through a linker including a tumor-associated protease cleavage site. A typical antibody includes a heavy chain and a light chain variable region, wherein the peptide forming the coiled coil is connected to the N-terminus of each peptide. A bivalent antibody has two binding sites, which may be the same or may be different. In normal monospecific antibodies, the binding sites are the same, and the antibody has two identical light and heavy chain pairs. In this case, each heavy chain is connected to the same coiled coil peptide, and each light chain is connected to the same coiled coil peptide (which may be the same or different from the peptide connected to the heavy chain).

[0097] In bispecific antibodies, the binding sites are different and are formed by two different heavy and light chain pairs. The binding site can be specific to different targets or to different epitopes on the same target. If the binding site is specific to different targets, the target can be on the same cell (e.g., two different surface antigens on cancer cells) or two different cells (e.g., a surface antigen on cancer cells and a surface antigen on immune cells such as T cells). For example, a binding site of a bispecific antibody can be for CD3 or 4-1BB.

[0098] In a bispecific antibody, the heavy chain and light chain variable regions of one binding site can be separately connected to a peptide that forms a coiled coil. The heavy chain and light chain variable regions of other binding sites may or may not be connected to a peptide that forms a coiled coil. If the heavy and light pairs of two binding sites are both connected to a peptide that forms a coiled coil, then usually both heavy chain variable regions are connected to the same type of peptide that forms a coiled coil, just like the two light chain variable regions. For example, if two binding sites are specific for surface antigens on the same tumor, then masking the two binding sites can be useful. For example, when one binding site is specific for a tumor surface antigen and the other is specific for a surface antigen on an immune cell, then masking one but not two binding sites can be useful. Binding sites that are specific for tumor surface antigens or for immune cell antigens can be masked. Some bispecific antibodies that are specific for both tumor surface antigens and immune cells have both sites masked.

[0099] The coiled coil can be formed by the same peptide forming a homodimer or two different peptides forming a heterodimer. To form a homodimer, the light antibody chain and the heavy antibody chain are connected to the same coiled coil-forming peptide. To form a heterodimer, the light antibody chain and the heavy antibody chain are connected to different coiled coil-forming peptides. For some pairs of coiled coil-forming peptides, it is preferred that one of the pairs is connected to the heavy chain of the antibody and the other is connected to the light chain of the antibody, although the reverse is also possible.

[0100] Each antibody chain can be linked to a single coiled-coil-forming peptide or to multiple (e.g., two, three, four, or five) such peptides in series. If the latter, the peptides in series are usually identical. Moreover, if a series connection is used, the light chain and heavy chain are usually linked to the same number of peptides.

[0101] The attachment of an antibody to a coiled-coil forming peptide can reduce the binding affinity of the antibody by, for example, up to 1 / 10, 1 / 50, 1 / 100, 1 / 200, 1 / 500, 1 / 1000, 1 / 1500, 1 / 2000, 1 / 4000, 1 / 5000, or 1 / 10000 relative to the same antibody without such attachment or after cleavage of such attachment. In some such antibodies, the binding affinity is reduced by 1 / 50 to 1 / 10000, 1 / 50 to 1 / 5000, 1 / 50 to 1 / 4000, 1 / 50 to 1 / 1000, 1 / 100 to 1 / 5000, 1 / 100 to 1 / 4000, 1 / 200 to 1 / 10000, 1 / 200 to 1 / 5000, 1 / 100 to 1 / 4000 / 50 to 1 / 1500, 1 / 100 to 1 / 1500, 1 / 200 to 1 / 1500, 1 / 200 to 1 / 1000, 1 / 500 to 1 / 1500, 1 / 50 to 1 / 1000, 1 / 100 to 1 / 1000, 1 / 200 to 1 / 1000, 1 / 500 to 1000, 1 / 50 to 1 / 500, 1 / 100 to 1 / 500.

[0102] Antibodies include non-human, humanized, human, chimeric and veneered antibodies, nanobodies, dAbs, scFVs, Fabs, and the like. Some of these antibodies include antibodies on the cell surface that are immunospecific for cancer cell antigens, preferably internalized in cells when the antibody binds. Targets that antibodies may be directed against include receptors on cancer cells and their ligands or counter-receptors (e.g., CD3, CD19, CD20, CD22, CD30, CD33, CD34, CD40, CD44, CD52, CD70, CD79a, CD123, Her-2, EphA2, lymphocyte-associated antigen 1, VEGF or VEGFR, CTLA-4, LIV-1, adhesion protein-4, CD74, and SLTRK-6).

[0103] In some embodiments, the antibodies include brentuximab or brentuximab vedotin, anti-CD30, alemtuzumab, anti-CD52, rituximab, anti-CD20, trastuzumab Her / neu, nimotuzumab, cetuximab, anti-EGFR, bevacizumab, anti-VEGF, palivizumab, anti-RSV, abciximab, GpIIb / IIIa, infliximab, adalimumab, certolizumab, golimumab TNF-α, TNF-alpha), baciliximab, daclizumab, anti-IL-2, omalizumab, anti-IgE, gemtuzumab or vadastuximab, anti-CD33, natalizumab, anti-VLA-4, vedolizumab α4β7 alpha4beta7), belimumab, anti-BAFF, otelixizumab, teplizumab, anti-CD3, ofatumumab, ocrelizumab, epratuzumab, anti-CD22, alemtuzumab, eculizumab, canakimumab, mepolizumab, reslizumab, tocilizumab, ustekinumab, and briakinumab.

[0104] Further embodiments are described in WO2018107125, which is incorporated herein by reference.

[0105] B. Collagen binding domain

[0106] Collagen is an extracellular matrix (ECM) protein that regulates a variety of cell biological functions, such as proliferation, differentiation and adhesion in normal and tumor tissues (Ricard-Blum, Cold Spring Harb Perspect Biol 3: a 004978, 2011). Collagen is the most abundant protein in the mammalian body and is present in almost all tissues as one or more of 28 isomers (Ricard-Blum, Cold Spring Harb Perspect Biol 3: a 004978, 2011). The subendothelial space of blood vessels is rich in collagen. Due to its insolubility under physiological conditions, collagen is almost absent in the blood (Dubois et al., Blood 107: 3902-06, 2006; Bergmeier and Hynes, Cold Spring Harbprospect Biol 4: a 005132, 2012). It has been reported that tumor vasculature is permeable due to structural abnormalities (Nagy et al., British journal of cancer 100:865, 2009). Therefore, collagen is exposed to tumors due to their leaky vasculature (Liang et al., Journal of controlled release 209:101-109, 2015; Liang et al., Sci Rep 6:18205, 2016; Yasunaga et al., Bioconjugate chemistry 22:1776-83, 2011; Xu et al., The Journal of cell biology 154:1069-80, 2001; Swartz and Lund, Nat Rev Cancer 12:210-19). Moreover, the content of collagen in tumor tissue is increased compared with normal tissue (Zhou et al., J Cancer 8:1466-76, 2017; Provenzano et al., BMC Med 6:11, 2008).

[0107] Von Willebrand factor (vWF) is a coagulation factor and binds to collagen type I and III and adhesion receptor GPIb on platelets (Lenting et al., Journal of thrombosis and haemostasis: JTH 10: 2428-37, 2012; Shahidi Advances in experimental medicine and biology 906: 285-306, 2017). When injured, collagen under endothelial cells is exposed to plasma, and vWF-collagen binding initiates the thrombotic cascade (Shahidi Advances in experimental medicine and biology 906: 285-306, 2017; Wu et al., Blood 99: 3623-28, 2002). Among the reported non-bacterial derived proteins / peptides, the vWF A domain has the highest affinity for collagen (Addi et al., Tissue Engineering Part B: Reviews, 2016). In particular, within domain A, domain A3 of vWF has been reported as a collagen binding domain (CBD) (Ribba et al., Thrombosis and haemostasis 86:848-54, 2001). As described above, the present inventors envision that fusion proteins with vWF A3 CBD can achieve targeted cytokine immunotherapy even when injected systemically, due to exposure of collagen through leaky tumor vasculature.

[0108] In some embodiments, the collagen binding domain comprises a polypeptide from decorin. Exemplary decorin polypeptides include human decorin or a fragment thereof, which can be represented by the following sequence:

[0109]

[0110] (SEQ ID NO:40), a peptide derived from human decorin: LRELHLDNNC (SEQ ID NO:41), and a peptide derived from bovine decorin: LRELHLNNNC (SEQ ID NO:44).

[0111] In some embodiments, the CBD comprises a polypeptide fragment from vWF. In some embodiments, the CBD comprises vWF A1, residues 1237 to 1458 (474 ​​to 695 of mature VWF) derived from the human sequence, or a fragment thereof, which can be represented by the amino acid sequence:

[0112]

[0113] In some embodiments, CBP includes all of vWF A3 or a fragment of vWF A3, which can be represented by the following amino acid sequence:

[0114] and

[0115] In some embodiments, the CBP comprises a vWF A3 domain polypeptide with a 6H tag having the following amino acid sequence:

[0116]

[0117] In some embodiments, CBP includes a peptide or polypeptide from von Willebrand Factor (vWF), such as a collagen binding peptide from vWF. The sequence of human vWF includes the following:

[0118]

[0119]

[0120] In some embodiments, the peptide is from the vWF A3 domain and has the following amino acid sequence (or a fragment thereof):

[0121]

[0122] The CBP peptide or polypeptide can be a peptide having 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity (or any range derivable therein) to the above-mentioned CBD peptide or peptide fragment, such as SEQ ID NO: 1, SEQ ID NO: 37 to SEQ ID NO: 41, and SEQ ID NO: 44 to SEQ ID NO: 46.

[0123] C. Connector

[0124] In some embodiments, the polypeptide comprises or further comprises a linker. The linker can be between any two polypeptide domains. In some embodiments, the polypeptide comprises a linker between CBP and a cytokine. In some embodiments, the polypeptide comprises a linker between CBP and a serum polypeptide. In some embodiments, the polypeptide comprises a linker between a masking agent and a cytokine. In some embodiments, the polypeptide comprises a linker between albumin and a cytokine. In some embodiments, the polypeptide comprises a linker between a therapeutic agent and a masking agent. In some embodiments, the polypeptide comprises a linker between a therapeutic agent and CBP. In some embodiments, the linker comprises one or more than one tumor-associated protease cleavage site. A tumor-associated protease cleavage site refers to a cleavage site recognized by a protease that is highly upregulated or enriched in a tumor microenvironment. Although a tumor-associated protease cleavage site may not be tumor-specific, meaning that the protease is expressed only in tumors, it is tumor-enriched, meaning that the protease is expressed in the tumor microenvironment at a level higher than that of normal tissues or most normal tissues. In some embodiments, the tumor-associated protease cleavage site comprises an amino acid sequence recognized and cleaved by a matrix metalloproteinase. For example, the tumor-associated protease cleavage site can be a site cleaved by MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP23A, MMP23B, MMP24, MMP25, MMP26, MMP27, MMP28, or a combination thereof. In some embodiments, the tumor-associated protease cleavage site comprises the MMP-responsive sequence of SEQ ID NO: 13: GLLSGRSDNH. In some embodiments, the tumor-associated protease cleavage site can be a site cleaved by thrombin. In some embodiments, the thrombin-responsive sequence comprises SEQ ID NO: 14: LVPRGS.

[0125] In some embodiments, two polypeptides such as CBP, serum proteins, therapeutic agents, masking agents, and cytokines can be connected by a bifunctional linker. A linker, such as an amino acid or a peptide mimetic sequence, can be inserted between peptide and / or antibody sequences. In one embodiment, the fynomer domain is connected to the heavy (H) chain or light (L) chain immediately after the last amino acid at the amino (NH2) end or carboxyl (C) end of the heavy (H) chain or light (L) chain. The linker can have one or more than one characteristics, including a flexible conformation, a hydrophobic or charged feature that cannot form an ordered secondary structure or can promote or interact with any domain. Examples of amino acids commonly found in flexible protein regions can include Gly, Asn, and Ser. For example, a suitable peptide linker can be GGGSGGGS (SEQ ID NO: 47) or (GGGS) n (SEQ ID NO: 48), wherein n = 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any range derivable therein). Other near-neutral amino acids, such as Thr and Ala, can also be used in the linker sequence. The length of the linker sequence can vary without significantly affecting the function or activity of the fusion protein (see, for example, U.S. Patent No. 6087329). The example of the linker may also include chemical moieties and conjugates, such as sulfo-succinimidyl derivatives (sulfo-SMCC, sulfo-SMPB), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG) and disuccinimidyl tartrate (DST). The example of the linker may also include a linear carbon chain, such as CN (wherein N=1 to 100 carbon atoms, such as N=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 or greater than 15). In some embodiments, the linker can be a dipeptide linker, such as a valine-citrulline (val-cit), a phenylalanine-lysine (phe-lys) linker, or a maleimidoadipic acid-valine-citrulline-p-aminobenzyloxycarbonyl (vc) linker. In some embodiments, the linker is sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (smcc). The conjugation of sulfo-smcc is carried out through the maleimide group that reacts with sulfhydryls (thiol, -SH), while its sulfo-NHS ester is reactive to primary amines (such as found in lysine and the N-terminus of proteins or peptides). In addition, the linker can be maleimidocaproyl (mc).

[0126] In some embodiments, the linker comprises one or more than one polypeptide that can be cleaved by an enzyme (protease) that is uniquely expressed or overexpressed in a cancer or tumor microenvironment compared to a healthy tissue or organ, i.e., serves as a substrate for the enzyme. Preferably, the enzyme can be found in the extracellular environment of the tumor. Examples of such proteases include: aspartic proteases (e.g., renin), fibroblast activation protein (FAP), aspartic cathepsins (e.g., cathepsin D, caspase 1, caspase 2, etc.), cysteine ​​cathepsins (cathepsin B), cysteine ​​proteases (e.g., legumin), disintegrin / metalloproteinases (ADAMs, e.g., ADAM8, ADAM9), disintegrin / metalloproteinases with thrombospondin motifs (ADAMTSs, e.g., ADAMTS1), integral membrane serine proteases (e.g., proteinase 2, MT-SP1 / proteinase, TMPRSS2, TMPRSS3, TMPRSS4), kallikrein-related peptidases (KLKs, e.g., KLK4, KLK5), matrix metalloproteinases (e.g., MMP-1, MMP-2, MMP-9), and serine proteases (e.g., cathepsin A, coagulation factor proteases such as elastase, plasmin, thrombin, PSA, uPA, factor Vila, factor Xa, and HCVNS3 / 4). Preferably, the protease is fibroblast activation protein (FAP), urokinase-type plasminogen activator (uPA, urokinase), MT-SP1 / macroproteinase, legumin, or matrix metalloproteinase (especially MMP-1, MMP-2 and MMP-9). Those skilled in the art will understand that the choice of enzyme and corresponding cleavable peptide will depend on the disease to be treated and the protease expressed by the affected tissue or organ.

[0127] Other examples of tumor-associated protease sites include LSGRSDNH (SEQ ID NO:49), which is cleaved by urokinase, proteases, or legumin; VPLSLYS (SEQ ID NO:50), which is cleaved by MMP2 or MMP9; PLGLAG (SEQ ID NO:51), which is cleaved by MMP2; VLVPMAMMAS (SEQ ID NO:52), which is cleaved by MMP1; XXQAR(A / V)X (SEQ ID NO:53), wherein X is any amino acid, which is cleaved by proteases; AGPR (SEQ ID NO:54), which is cleaved by proteases; AANL (SEQ ID NO:55) and PTNL (SEQ ID NO:56), which are cleaved by legumin; and TSGRSANP (SEQ ID NO:57).

[0128] 41 ,42,43,44,45,46,47,48,49,50,51 ,52,53,54,55,56,57,58,59,60,61 ,62,63,64,65,66,67,68,69,70,71 ,72,73,74,75,76,77,78,79,80,81 ,82,83,84,85,86,87,88,89,90,91 ,92,93,94,95,96,97,98,99,100,101 ,102,103,104,105,106,107,108,109,110 A linker of 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids (or any range derivable therein) can be isolated or positioned between any two of CBP, serum protein, therapeutic agent, sequestering agent, and cytokine.

[0129] The linker may comprise the sequence of SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 47 to SEQ ID NO: 57, or a peptide having 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity (or any range derivable therein) to SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 47 to SEQ ID NO: 57.

[0130] Other examples of tumor-associated protease sites include those in the following table:

[0131]

[0132]

[0133] D. Serum protein

[0134] In some embodiments, the polypeptides of the present disclosure are further linked to serum proteins. Serum proteins include, for example, albumin, globulin, and fibrinogen. Globulins include alpha 1 globulin, alpha 2 globulin, beta globulin, and gamma globulin. Albumin can be mouse, human, bovine, or any other homologous albumin protein. In some embodiments, albumin includes human serum albumin, which is encoded by the ALB gene and is exemplified by the following amino acid sequence:

[0135]

[0136] In some embodiments, the albumin comprises mouse albumin having the following sequence:

[0137]

[0138] In some embodiments, the serum protein comprises a polypeptide of SEQ ID No: 42 or SEQ ID No: 43, or a fragment thereof, or a polypeptide having 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity (or any range derivable therein) to SEQ ID NO: 42, SEQ ID No: 43, or a fragment thereof.

[0139] E. Polypeptide Embodiments

[0140] Examples of specific polypeptide embodiments are as follows:

[0141]

[0142]

[0143]

[0144]

[0145] In some embodiments, the polypeptide has 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity to a polypeptide of the present disclosure, e.g., SEQ ID NO:7 to SEQ ID NO:12 and SEQ ID NO:15 to SEQ ID NO:18, or a fragment thereof.

[0146] F. Protein Labeling

[0147] In some embodiments, the polypeptide further comprises a protein tag. The protein tag can be used, for example, for protein purification and / or immunoassay. Exemplary protein tags include AviTag, a peptide that allows biotinylation by the BirA enzyme and thus allows separation of proteins by streptavidin (GLNDIFEAQKIEWHE (SEQ ID NO: 82)); Calmodulin-tag, a peptide bound by the protein Calmodulin (KRRWKKNFIAVSAANRFKKISSSGAL (SEQ ID NO: 83)); Polyglutamate, a peptide that effectively binds to anion exchange resins such as Mono-Q (EEEEEE (SEQ ID NO: 84)); E-tag, a peptide recognized by an antibody (GAPVPYPDPLEPR (SEQ ID NO: 102)); FLAG-tag, a peptide recognized by an antibody (DYKDDDDK (SEQ ID NO: 85)); HA tag, a peptide from hemagglutinin recognized by an antibody (YPYDVPDYA (SEQ ID NO: 86)). ID NO:86); His-tag, 5 to 10 histidines bound by nickel or cobalt chelates (HHHHHH (SEQ ID NO:87)); Myc-tag, a peptide derived from c-myc recognized by antibodies (EQKLISEEDL (SEQ ID NO:88)); NE-tag, a novel 18-amino acid synthetic peptide recognized by monoclonal IgG1 antibodies (TKENPRSNQEESYDDNES (SEQ ID NO:89)), which can be used in a wide range of applications including immunowestern blotting, ELISA, flow cytometry, immunocytochemistry, immunoprecipitation and affinity purification of recombinant proteins; S-tag, a peptide derived from ribonuclease A (KETAAAKFERQHMDS (SEQ ID NO:90)); SBP-tag, a peptide bound to streptavidin (MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP (SEQ ID NO:91)); Softag 1, for mammalian expression (SLAELLNAGLGGS (SEQ ID NO: 92)); Softag 3, for prokaryotic expression (TQDPSRVG (SEQ ID NO: 93)); Streptococcus-tag, a peptide that binds to streptavidin or modified streptavidin (called streptactin) (Strep-tag II: WSHPQFEK (SEQ ID NO: 94)); TC tag, a tetracysteine ​​tag recognized by FlAsH and ReAsH bisarsenic compounds (CCPGCC (SEQ ID NO: 95)); V5 tag, a peptide recognized by antibodies (GKPIPNPLLGLDST (SEQ ID NO: 96));VSV-tag, a peptide recognized by an antibody (YTDIEMNRLGK (SEQ ID NO:97)); Xpress tag (DLYDDDDK (SEQ ID NO:98)); covalent peptide tag; Isopeptag, a peptide covalently bound to the pilin-C protein (TDKDMTITFTNKKDAE (SEQ ID NO:99)); Spy tag, a peptide covalently bound to the SpyCatcher protein (AHIVMVDAYKPTK (SEQ ID NO:100)); Snoop tag, a peptide covalently bound to the SnoopCatcher protein (KLGDIEFIKVNK (SEQ ID NO:101)). NO:101)); BCCP (biotin carboxyl carrier protein), a protein domain biotinylated by BirA that can be recognized by streptavidin; Glutathione-S-transferase-tag, a protein that binds to immobilized glutathione; Green fluorescent protein-tag, a protein that is autofluorescent and can bind to nanobodies; Halo tag, a mutant bacterial haloalkane dehalogenase that is covalently linked to an active haloalkane substrate, which allows for linkage to a variety of substrates; Maltose binding protein-tag, a protein that binds to amylose agarose; Nus-tag; Thioredoxin-tag; Fc-tag, which is derived from the immunoglobulin Fc region, allowing dimerization and solubilization. Protein-A agarose, designed intrinsic disorder tags containing disorder-promoting amino acids (P, E, S, T, A, Q, G), and Ty tags can be used for purification. In some embodiments, the polypeptide comprises a 6H tag of SEQ ID NO:87. ;

[0148] II. Composition of Protein

[0149] The polypeptides or polynucleotides, e.g., CBDs, serum proteins, therapeutic agents, masking agents, linkers, or cytokine polypeptides of the present disclosure may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 or more variant amino acids or nucleotide substitutions, or may be substituted with SEQ ID NO: 1 to SEQ ID NO: 2 at least, or at most, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 of NO: 190. ,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129 , 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165,166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、191、192、193、194、195、196、197、198、 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 500, 550, 1000 or more, or any range derivable therein, of contiguous amino acids or nucleotides having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 10 ... 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% similarity, identity or homology.

[0150] The polypeptides disclosed herein, such as CBD, serum protein, therapeutic agent, masking agent, linker, or cytokine polypeptides, may comprise SEQ ID NO: 1 to SEQ ID 43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 , 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163 ,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,40, 500, 550, 1000 or more than 1000 consecutive amino acids or any range derivable therein. ,

[0151] In some embodiments, the polypeptide of the present disclosure may comprise SEQ ID NO: 1 to SEQ ID 47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110 1, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212,213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、 238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、 263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、 288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、 313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、 338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、 363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、 388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、 438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、 463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、 488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、 513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、 538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、 563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、 588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613, 614 or 615 (or any range derivable therein) amino acids.

[0152] In some embodiments, a polypeptide of the present disclosure, such as a CBD, a serum protein, a therapeutic agent, a masking agent, a linker, or a cytokine polypeptide, may comprise SEQ ID NO: 1 to SEQ ID at least, at most, about, or exactly 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 of NO: 190. , 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112 , 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159 9, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、 231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、 256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、 281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、 306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、 331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、 356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、 381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、 431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、 456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、 481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、 506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、 531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、 556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、 581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606, 607, 608, 609, 610, 611, 612, 613, 614 or 615 (or any range derivable therein) consecutive amino acids.

[0153] In some embodiments, a polypeptide, such as a CBD, a serum protein, a therapeutic agent, a masking agent, a linker, or a cytokine polypeptide, may comprise SEQ ID NO: 1 to SEQ ID at least, at most, about, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 7, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112 , 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 1 59, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、 231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、 256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、 281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、 306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、 331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、 356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、 381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、 431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、 456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、 481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、 506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、 531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、 556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、 581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606, 607, 608, 609, 610, 611, 612, 613, 614 or 615 (or any range derivable therein) consecutive amino acids, which are identical to SEQ ID NO: 1 to SEQ ID NO: 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% similarity, identity, or homology to one of NO:190.

[0154] The polypeptides of the present disclosure, e.g., CBDs, serum proteins, therapeutic agents, masking agents, linkers or cytokine polypeptides can have at least, at most or about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% (or any range derivable therein) similarity, identity or homology to one of SEQ ID NO: 1 to SEQ ID NO: 190.

[0155] 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 1, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118、119、120、121、122、123、124、125、126、127、128、129、130、131、132、133、134、135、136、137、138、139、140、141、142、 143、144、145、146、147、148、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、 168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、191、192、 193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、238、239、240、241、242、 243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、 268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、 293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、 318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、 343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、 368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、 393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442 2,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466, 467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491 1, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、54 0, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589 9, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613,614 or 615 (or any range derivable therein) permutations.

[0156] The substitution may be between SEQ ID NO: 1 and SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 of the amino acid selected from NO:190. , 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th 7th, 98th, 99th, 100th, 101st, 102nd, 103rd, 104th, 105th, 106th, 107th, 108th, 109th, 110th, 111th, 112th, 113th, 114th, 115th, 116th, 117th, 118th, 119th, 120th, 121st, 122nd, 123rd, 124th, 125th, 126th, 127th, 128th, 129th, 130th, 131st, 132nd, 133rd, 134th, 135th, 136th, 137th, 138th 38th, 139th, 140th, 141st, 142nd, 143rd, 144th, 145th, 146th, 147th, 148th, 149th, 150th, 151st, 152nd, 153rd, 154th, 155th, 156th, 157th, 158th, 159th, 160th, 161st, 162nd, 163rd, 164th, 165th, 166th, 167th, 168th, 169th, 170th, 171st, 172nd, 173rd, 174th, 175th, 176th, 177th, 178th,179th, 180th, 181st, 182nd, 183rd, 184th, 185th, 186th, 187th, 188th, 189th, 190th, 191st, 192nd, 193rd, 194th, 195th, 196th, 197th, 198th, 199th 200th, 201st, 202nd, 203rd, 204th, 205th, 206th, 207th, 208th, 209th, 210th, 211th, 212th, 213th, 214th, 215th, 216th, 217th, 218th, 219th, 220th 0th, 221st, 222nd, 223rd, 224th, 225th, 226th, 227th, 228th, 229th, 230th, 231st, 232nd, 233rd, 234th, 235th, 236th, 237th, 238th, 239th, 240th, 241st, 242nd, 243rd, 244th, 245th, 246th, 247th, 248th, 249th, 250th, 251st, 252nd, 253rd, 254th, 255th, 256th, 257th, 258th, 259th, 260th, 261st, 262nd, 263rd, 264th, 265th, 266th, 267th, 268th, 269th, 270th, 271st, 272nd, 273rd, 274th, 275th, 276th, 277th, 278th, 279th, 280th, 281st, 282nd 283rd, 284th, 285th, 286th, 287th, 288th, 289th, 290th, 291st, 292nd, 293rd, 294th, 295th, 296th, 297th, 298th, 299th, 300th, 301st, 302nd, 303rd 304th, 305th, 306th, 307th, 308th, 309th, 310th, 311th, 312th, 313th, 314th, 315th, 316th, 317th, 318th, 319th, 320th, 321st, 322nd, 323rd, 324th, 325th, 326th, 327th, 328th, 329th, 330th, 331st, 332nd, 333rd, 334th, 335th, 336th, 337th, 338th, 339th, 340th, 341st, 342nd, 343rd, 344th,345th, 346th, 347th, 348th, 349th, 350th, 351st, 352nd, 353rd, 354th, 355th, 356th, 357th, 358th, 359th, 360th, 361st, 362nd, 363rd, 364th, 365th 366th, 367th, 368th, 369th, 370th, 371st, 372nd, 373rd, 374th, 375th, 376th, 377th, 378th, 379th, 380th, 381st, 382nd, 383rd, 384th, 385th, 386th 6th, 387th, 388th, 389th, 390th, 391st, 392nd, 393rd, 394th, 395th, 396th, 397th, 398th, 399th, 400th, 401st, 402nd, 403rd, 404th, 405th, 406th, 407th, 408th, 409th, 410th, 411th, 412th, 413th, 414th, 415th, 416th, 417th, 418th, 419th, 420th, 421st, 422nd, 423rd, 424th, 425th, 426th, 427th, No. 428, No. 429, No. 430, No. 431, No. 432, No. 433, No. 434, No. 435, No. 436, No. 437, No. 438, No. 439, No. 440, No. 441, No. 442, No. 443, No. 444, No. 445, No. 446, No. 447, No. 448 449th, 450th, 451st, 452nd, 453rd, 454th, 455th, 456th, 457th, 458th, 459th, 460th, 461st, 462nd, 463rd, 464th, 465th, 466th, 467th, 468th, 469th 9th, 470th, 471st, 472nd, 473rd, 474th, 475th, 476th, 477th, 478th, 479th, 480th, 481st, 482nd, 483rd, 484th, 485th, 486th, 487th, 488th, 489th, 490th, 491st, 492nd, 493rd, 494th, 495th, 496th, 497th, 498th, 499th, 500th, 501st, 502nd, 503rd, 504th, 505th, 506th, 507th, 508th, 509th, 510th,511th, 512th, 513th, 514th, 515th, 516th, 517th, 518th, 519th, 520th, 521st, 522nd, 523rd, 524th, 525th, 526th, 527th, 528th, 529th, 530th, 531st, 532nd, 533rd, 534th, 535th, 536th, 537th, 538th, 539th, 540th, 541st, 542nd, 543rd, 544th, 545th, 546th, 547th, 548th, 549th, 550th, 551st, 552nd, 553rd, 554th, 555th, 556th, 557th, 558th, 559th, 560th, 561st, 562nd, 563rd 3rd, 564th, 565th, 566th, 567th, 568th, 569th, 570th, 571st, 572nd, 573rd, 574th, 575th, 576th, 577th, 578th, 579th, 580th, 581st, 582nd, 583rd, 584th, 585th, 586th, 587th, 588th, 589th , 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, or 615. One or more of these substitutions may be specifically excluded from the embodiments.

[0157] Peptides, polypeptides and proteins of the present disclosure, such as CBDs, serum proteins, therapeutic agents, masking agents, linkers, or cytokine polypeptides, that are at least, have at least or have 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to any one of SEQ ID NO: 1 to SEQ ID NO: 190, comprise amino acids 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 ,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,8 1, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 , 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 1 47, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102 2, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 、139、140、141、142、143、144、145、146、147、148、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204 or 205 (or any range derivable therein).

[0158] Substitution changes generally contain an exchange of one amino acid for another at one or more than one site within a protein, and can be designed to adjust one or more than one property of a polypeptide, with or without loss of other functions or properties. Substitutions can be conservative, i.e., one amino acid is replaced by an amino acid of similar shape and charge. Conservative substitutions are well known in the art, and include, for example, the following changes: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine ​​to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to aspartic acid or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Alternatively, the substitution may be non-conservative, thereby affecting the function or activity of the polypeptide. Non-conservative changes generally involve replacing a residue with a chemically different residue, such as replacing a non-polar or uncharged amino acid with a polar or charged amino acid, or vice versa. One or more of these substitutions may be specifically excluded from the embodiment.

[0159] The protein can be recombinant, or synthesized in vitro. Alternatively, a non-recombinant or recombinant protein can be isolated from bacteria. It is also contemplated that bacteria containing such variants can be implemented in compositions and methods. Therefore, the protein does not need to be isolated.

[0160] The term "functionally equivalent codons" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also to codons that encode biologically equivalent amino acids.

[0161] It is also understood that the amino acid and nucleic acid sequences may contain additional residues, such as additional N-terminal or C-terminal amino acids, or 5' or 3' sequences, respectively, but still essentially as described above in one of the sequences disclosed herein, as long as the sequence meets the above criteria, including maintenance of biological protein activity when it comes to protein expression. The addition of terminal sequences is particularly applicable to nucleic acid sequences that may contain various non-coding sequences flanking the 5' portion or 3' portion of the coding region.

[0162] Below is based on the discussion of changing the amino acid of albumen to produce equivalent or even improved second generation molecules.For example, some amino acid can replace other amino acid in protein structure, and can not obviously lose the binding capacity of interaction.Structure such as enzyme catalytic domain or interaction component can make amino acid be replaced to keep this function.Because it is the interaction capacity and property of albumen that define the biological function activity of albumen, some amino acid replacement can be completed in protein sequence and in the DNA coding sequence of its bottom, and still produce albumen with similar properties.Therefore the inventor expects that various changes can be completed in the DNA sequence of gene, and there is no observable loss of its biological efficacy or activity.

[0163] In other embodiments, the function of polypeptide is changed by introducing one or more than one displacement. For example, some amino acids can replace other amino acids in protein structure, and the purpose is to change the interaction binding ability of interaction components. Structures such as protein interaction domains, nucleic acid interaction domains and catalytic sites can make amino acids replaced to change this function. Because it is the interaction ability and properties of protein that limit the biological function activity of protein, some amino acid replacement can be completed in protein sequence and in the DNA coding sequence of its bottom layer, and still produce proteins with different properties. Therefore, the inventor expects that various changes can be completed in the DNA sequence of gene, wherein its biological efficacy or active changes can be observed.

[0164] In making such changes, the hydropathic index of the amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on proteins is generally understood in the art (Kyte and Doolittle, 1982). The relative hydropathicity of the receiving amino acids contributes to the secondary structure of the resulting protein, which in turn defines the interaction of the protein with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc.

[0165] It is also understood in the art that replacement of similar amino acids can be effectively accomplished based on hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, illustrates that the maximum local average hydrophilicity of a protein, as determined by the hydrophilicity of its adjacent amino acids, is related to the biological properties of the protein. It should be understood that an amino acid can be replaced with another amino acid having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.

[0166] As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chains, e.g., their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions that take into account various of the foregoing properties are well known, and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamic acid and aspartic acid; and valine, leucine, and isoleucine.

[0167] In specific embodiments, all or part of the proteins described herein may also be synthesized in solution or on a solid support according to conventional techniques. Various automated synthesizers are commercially available and may be used according to known protocols. See, for example, Stewart and Young, (1984); Tam et al., (1983); Merrifield, (1986); and Barany and Merrifield (1979), each of which is incorporated herein by reference. Alternatively, recombinant DNA techniques may be employed in which a nucleotide sequence encoding a peptide or polypeptide is inserted into an expression vector, transformed or transfected into a suitable host cell, and cultured under conditions suitable for expression.

[0168] One embodiment includes transferring genes to cells, including microorganisms, for the production and / or presentation of protein purposes. The gene for the protein of interest can be transferred to a suitable host cell, and then the cell is cultured under suitable conditions. Nucleic acids encoding virtually any polypeptide can be used. The generation of recombinant expression vectors and the elements included therein are discussed herein. Alternatively, the protein to be produced can be an endogenous protein that is typically synthesized by cells for protein production.

[0169] III. Nucleic Acids

[0170] In certain embodiments, the disclosure relates to recombinant polynucleotides encoding proteins, polypeptides and peptides of the invention, such as CBD, serum proteins, therapeutic agents, masking agents, linkers or cytokine polypeptides and / or other molecules. Therefore, certain embodiments relate to nucleotides encoding CBD, serum proteins, therapeutic agents, masking agents, linkers or cytokine polypeptides or fragments thereof.

[0171] As used in the present application, the term "polynucleotide" refers to a nucleic acid molecule that is recombinant or has been separated from total genomic nucleic acid. Included in the term "polynucleotide" are oligonucleotides (nucleic acids having 100 or less than 100 residues in length), i.e. recombinant vectors, including for example plasmids, cosmids, phagemids, viruses, etc. In some aspects, polynucleotides include the regulatory sequences that are basically separated from their naturally occurring genes or protein coding sequences. Polynucleotides can be single-stranded (coding or antisense) or double-stranded, and can be RNA, DNA (genomic, cDNA or synthetic), its analog or its combination. Other coding or non-coding sequences can but need not be present in the polynucleotides.

[0172] In this regard, the term "gene", "polynucleotide" or "nucleic acid" is used to refer to a nucleic acid encoding a protein, polypeptide or peptide (including any sequences required for correct transcription, post-translational modification or localization). As will be appreciated by those skilled in the art, the term includes genomic sequences, expression cassettes, cDNA sequences and smaller engineered nucleic acid segments that express or may be suitable for expressing proteins, polypeptides, domains, peptides, fusion proteins and mutants. A nucleic acid encoding all or part of a polypeptide may comprise the following consecutive nucleic acid sequences: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 301, 310, 320, 330, 340, 350, 360, 370, 380, 390, 401, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 701 00, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050, 1060, 1070, 1080, 1090, 1095, 1100, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 9000, 10000 or more than 10000 nucleotides, nucleosides or base pairs (or any range derivable therein), including all values ​​and ranges therebetween. It is also contemplated that a particular polypeptide may be encoded by a nucleic acid that contains variations with slightly different amino acid sequences but still encodes the same or substantially similar protein.

[0173] In specific embodiments, the present invention relates to isolated nucleic acid segments and recombinant vectors comprising nucleic acid sequences encoding polypeptides or peptides of the present disclosure. The term "recombinant" can be used in conjunction with a polynucleotide or polypeptide, and generally refers to a polypeptide or polynucleotide produced and / or manipulated in vitro, or a replicated product of such a molecule.

[0174] In other embodiments, the present invention relates to isolated nucleic acid segments and recombinant vectors comprising a nucleic acid sequence encoding a polypeptide or peptide of the present disclosure.

[0175] The nucleic acid segments used in the present disclosure can be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, etc., so that their total length can vary significantly. It is thus expected that nucleic acid fragments of almost any length can be used, wherein the total length is preferably limited by the ease of preparation and use in the expected recombinant nucleic acid scheme. In some cases, the nucleic acid sequence can encode a polypeptide sequence with an additional heterologous coding sequence, for example to allow purification, transport, secretion, post-translational modification of the polypeptide, or for therapeutic benefits, such as targeting or efficacy. As discussed above, a tag or other heterologous polypeptide can be added to a modified polypeptide coding sequence, wherein "heterologous" refers to a polypeptide that is not identical to the modified polypeptide.

[0176] In some embodiments, the present disclosure provides polynucleotide variants having substantial identity to the sequences disclosed herein; those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or greater than 99% (including all values ​​and ranges therebetween) sequence identity compared to the polynucleotide sequences of the present disclosure using the methods described herein (e.g., BLAST analysis using standard parameters).

[0177] The present disclosure also contemplates the use of polynucleotides that are complementary to all of the above-described polynucleotides.

[0178] A. Carrier

[0179] The polypeptides of the present disclosure can be encoded by nucleic acid molecules contained in vectors. The term "vector" is used to refer to carrier nucleic acid molecules into which heterologous nucleic acid sequences can be inserted for introduction into cells, where they can be replicated and expressed. Nucleic acid sequences can be "heterologous", meaning that they are in an environment different from the cell into which the vector is introduced, or in an environment different from the nucleic acid into which the nucleic acid sequence is incorporated, and they contain sequences homologous to sequences in cells or nucleic acids rather than in locations within host cells or nucleic acids where they are not usually found. Vectors include DNA, RNA, plasmids, cosmids, viruses (bacteriophages, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). Those skilled in the art are well able to construct vectors by standard recombinant techniques (e.g., Sambrook et al., 2001; Ausubel et al., 1996, both of which are incorporated herein by reference). In addition to encoding the polypeptides of the present disclosure, vectors can also encode other polypeptide sequences, such as one or more than one other bacterial peptides, tags, or immunogenicity enhancing peptides. Useful vectors encoding these fusion proteins include pIN vectors (Inouye et al., 1985), vectors encoding a stretch of histidine, and pGEX vectors for production of soluble glutathione S-transferase (GST) fusion proteins for subsequent purification and isolation or cleavage.

[0180] The term "expression vector" refers to a vector containing a nucleic acid sequence that encodes at least part of a gene product that can be transcribed. In some cases, the RNA molecule is then translated into a protein, polypeptide or peptide. An expression vector may contain various "control sequences," which refer to nucleic acid sequences required for the transcription and possible translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and transfer, vectors and expression vectors may also contain nucleic acid sequences that have other functions, and are described herein.

[0181] B. Promoters and Enhancers

[0182] A "promoter" is a control sequence. A promoter is generally a region where a nucleic acid sequence controls the initiation and rate of transcription. It may contain genetic factors where regulatory proteins and molecules may bind, for example, RNA polymerase and other transcription factors. The phrases "operably positioned," "operably linked," "under control," and "under transcriptional control" indicate that a promoter is in the correct functional position and / or orientation relative to a nucleic acid sequence to control the initiation of transcription of the sequence and the expression of the sequence. A promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence that is involved in the transcriptional activation of a nucleic acid sequence.

[0183] Of course, it is important to employ promoters and / or enhancers that are effective in directing expression of the DNA segment in the cell type or organism selected for expression. The use of promoter, enhancer, and cell type combinations for protein expression is generally known to those skilled in the art of molecular biology (see Sambrook et al., 2001, which is incorporated herein by reference). The promoters used may be constitutive, tissue-specific, or inducible, and in certain embodiments may direct high-level expression of the introduced DNA segment under specified conditions, such as large-scale production of recombinant proteins or peptides.

[0184] It is believed that the specific promoter used to control the expression of the peptide or protein encoding the polynucleotide of the present invention is not critical, as long as it is capable of expressing the polynucleotide in the targeted cell, preferably a bacterial cell. When targeting human cells, it is preferred that the polynucleotide coding region is placed adjacent to and under the control of a promoter that is capable of being expressed in human cells. Typically, such promoters may include bacterial, human or viral promoters.

[0185] C. Initiation signal and internal ribosome binding site (IRES)

[0186] Effective translation of the coding sequence may also require specific initiation signals. These signals include the ATG initiation codon or adjacent sequences. It may be necessary to provide exogenous translation control signals, including the ATG initiation codon. One of ordinary skill in the art will be able to easily determine this and provide the necessary signals.

[0187] In some embodiments of the present invention, internal ribosome entry site (IRES) elements are used to generate multi-gene or multi-cistronic information. IRES elements can bypass the ribosome scanning model of 5' methylated Cap-dependent translation and start translation at internal sites (Pelletier and Sonenberg, 1988; Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by IRES, thereby creating multi-cistronic information. Multiple genes can be effectively expressed using a single promoter / enhancer to transcribe a single message (see U.S. Patents 5925565 and 5935819, incorporated herein by reference).

[0188] D. Optional and filterable markers

[0189] In some embodiments of the present invention, cells containing nucleic acid constructs of the present disclosure can be identified in vitro or in vivo by encoding a screenable or selectable marker in an expression vector. After transcription and translation, the marker can confer recognizable changes to the cell, thereby easily identifying cells containing the expression vector. Generally, a selectable marker is a marker that confers a property that allows selection. A positive selection marker is a marker in which the marker's presence allows its selection, while a negative selection marker is a marker in which its presence prevents its selection. An example of a positive selection marker is a drug resistance marker.

[0190] E. Host cells

[0191] As used herein, the terms "cell", "cell line" and "cell culture" can be used interchangeably. All of these terms also include their offspring, which are any and all offspring. It should be understood that all offspring may not be identical due to intentional or unintentional mutations. In the case of expressing heterologous nucleic acid sequences, "host cell" refers to a prokaryotic cell or a eukaryotic cell, and includes any transformable organism capable of replicating a vector or expressing a heterologous gene encoded by a vector. Host cells can and have been used as receptors for vectors or viruses. Host cells can be "transfected" or "transformed", which refers to the process by which exogenous nucleic acids, such as recombinant protein coding sequences, are transferred or introduced into host cells. Transformed cells include primary subject cells and their offspring.

[0192] Host cells can be derived from prokaryotes or eukaryotes, including bacteria, yeast cells, insect cells and mammalian cells, for replication of the vector or expression of part or all of the nucleic acid sequence. Many cell lines and cultures can be used as host cells and are available through the American Type Culture Collection (ATCC), an archival depository of living cultures and genetic materials (www.atcc.org).

[0193] F. Expression system

[0194] There are a large number of expression systems that comprise at least part or all of the above-mentioned compositions. Prokaryotic and / or eukaryotic systems can be used for the present invention to produce polypeptides, proteins and peptides of nucleic acid sequences or their homology. Many such systems are widely available commercially.

[0195] Insect cell / baculovirus systems can produce high levels of protein expression of heterologous nucleic acid segments, such as described in U.S. Pat. Nos. 5,871,986 and 4,879,236, both of which are incorporated herein by reference, and such systems can be used, for example, from By Name 2.0 Purchased and from By the name BACPACK TM BACULOVIRUS EXPRESSION SYSTEM was purchased.

[0196] In addition to the expression system disclosed in the present invention, other examples of expression systems include A COMPLETE CONTROL inducible mammalian expression system, which involves synthesizing an ecdysone inducible receptor or its pET expression system, an E. coli expression system. Another example of an inducible expression system can be obtained from Get, it carries T-REX TM (tetracycline regulated expression) system, an inducible mammalian expression system using the full-length CMV promoter. Also provided is a yeast expression system called Pichia methanolica expression system, which is designed for high-level production of recombinant proteins in the methylotrophic yeast Pichia methanolica. Those skilled in the art will know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its homologous polypeptide, protein or peptide.

[0197] IV. Other Therapies

[0198] A. Immunotherapy

[0199] In some embodiments, the method includes administering cancer immunotherapy. Cancer immunotherapy (sometimes referred to as immuno-oncology, abbreviated as IO) is the use of the immune system to treat cancer. Immunotherapy can be divided into active, passive or combined immunity (active and passive). These methods take advantage of the fact that cancer cells usually have molecules on their surface that can be detected by the immune system, called tumor-associated antigens (TAA); they are usually proteins or other macromolecules (such as carbohydrates). Active immunotherapy guides the immune system to attack tumor cells by targeting TAA. Passive immunotherapy enhances existing anti-tumor responses and includes the use of monoclonal antibodies, lymphocytes and cytokines. Immunotherapy useful in the methods of the present disclosure is described below.

[0200] 1. Checkpoint inhibitors and combination therapy

[0201] Embodiments of the present disclosure may include the administration of immune checkpoint inhibitors (also referred to as checkpoint inhibitor therapy), which are also described below.

[0202] a. PD-1, PD-L1, and PD-L2 inhibitors

[0203] PD-1 can act in the tumor microenvironment where T cells encounter infection or tumors. Activated T cells upregulate PD-1 and continue to express it in peripheral tissues. Cytokines such as IFN-γ induce PD-L1 expression on epithelial cells or tumor cells. PD-L2 is expressed on macrophages and dendritic cells. The main role of PD-1 is to limit the activity of effector T cells in the periphery and prevent excessive damage to tissues during immune responses. The inhibitors disclosed herein can block one or more than one function of PD-1 and / or PD-L1 activity.

[0204] Alternative names for "PD-1" include CD279 and SLEB2. Alternative names for "PD-L1" include B7-H1, B7-4, CD274, and B7-H. Alternative names for "PD-L2" include B7-DC, Btdc, and CD273. In some embodiments, PD-1, PD-L1, and PD-L2 are human PD-1, PD-L1, and PD-L2.

[0205] In some embodiments, a PD-1 inhibitor is a molecule that inhibits the binding of PD-1 to its ligand binding partner. In a specific aspect, the PD-1 ligand binding partner is PD-L1 and / or PD-L2. In another embodiment, a PD-L1 inhibitor is a molecule that inhibits the binding of PD-L1 to its binding partner. In a specific aspect, the PD-L1 binding partner is PD-1 and / or B7-1. In another embodiment, a PD-L2 inhibitor is a molecule that inhibits the binding of PD-L2 to its binding partner. In a specific aspect, the PD-L2 binding partner is PD-1. The inhibitor can be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide. Exemplary antibodies are described in U.S. Patents Nos. 8,735,553, 8,354,509, and 8,008,449, all of which are incorporated herein by reference. Other PD-1 inhibitors for use in the methods and compositions provided herein are known in the art, such as described in U.S. Patent Applications US2014 / 0294898, US2014 / 022021, and US2011 / 0008369, all of which are incorporated herein by reference.

[0206] In some embodiments, the PD-1 inhibitor is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, and pidilizumab. In some embodiments, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-L1 inhibitor includes AMP-224. Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and is an anti-PD-1 antibody described in WO2006 / 121168. Pembrolizumab, also known as MK-3475, Merck3475, lambrolizumab, and SCH-900475, are anti-PD-1 antibodies described in WO2009 / 114335. Pidilizumab, also known as CT-011, hBAT or hBAT-1, is an anti-PD-1 antibody described in WO2006 / 101611. AMP-224, also known as B7-DCIg, is a PD-L2-Fc fusion soluble receptor described in WO2010 / 027827 and WO2011 / 066342. Additional PD-1 inhibitors include MEDI0680, also known as AMP-514 and REGN2810.

[0207] In some embodiments, immune checkpoint inhibitors are PD-L1 inhibitors, such as Durvalumab (also known as MEDI4736), atezolizumab (also known as MPDL3280A), avelumab (also known as MSB00010118C, MDX-1105, BMS-936559) or combinations thereof. In some aspects, immune checkpoint inhibitors are PD-L2 inhibitors, such as rHIgM12B7.

[0208] In some embodiments, the inhibitor includes the heavy and light chain CDRs or VRs of nivolumab, pembrolizumab or pidilizumab. Therefore, in one embodiment, the inhibitor includes CDR1, CDR2 and CDR3 domains in the VH region of nivolumab, pembrolizumab or pidilizumab, and CDR1, CDR2 and CDR3 domains in the VL region of nivolumab, pembrolizumab or pidilizumab. In another embodiment, the antibody competes with the above-mentioned antibodies for binding to the same epitope on PD-1, PD-L1 or PD-L2 and / or binds to the same epitope on PD-1, PD-L1 or PD-L2. In another embodiment, the antibody has a variable region amino acid sequence identity of at least about 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% (or any range derivable therein) with the above-mentioned antibodies.

[0209] b. CTLA-4, B7-1 and B7-2

[0210] Another immune checkpoint that can be targeted in the methods provided herein is cytotoxic T lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has Genbank accession number L15006. CTLA-4 is present on the surface of T cells and can act as a "close" switch when bound to B7-1 (CD80) or B7-2 (CD86) on the surface of antigen-presenting cells. CTLA-4 is a member of the immunoglobulin superfamily, expressed on the surface of helper T cells, and transmits inhibitory signals to T cells. CTLA-4 is similar to T cell co-stimulatory protein CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 transmits inhibitory signals to T cells, while CD28 transmits stimulatory signals. Intracellular CTLA-4 is also present in regulatory T cells and may be important for their function. Activation of T cells by T cell receptors and CD28 leads to increased expression of inhibitory receptor CTLA-4 for B7 molecules. The inhibitors disclosed herein can block one or more than one function of CTLA-4, B7-1 and / or B7-2 activity. In some embodiments, the inhibitor blocks the interaction between CTLA-4 and B7-1. In some embodiments, the inhibitor blocks the interaction between CTLA-4 and B7-2.

[0211] In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.

[0212] Anti-human-CTLA-4 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present method can be produced using methods well known in the art. Alternatively, anti-CTLA-4 antibodies recognized in the art can be used. For example, anti-CTLA-4 antibodies described in the following disclosures can be used in the methods disclosed herein: US 8119129, WO 01 / 14424, WO 98 / 42752; WO 00 / 37504 (Cp675206, also known as tremelimumab; formerly ticilimumab), U.S. Patent No. 6207156; Hurwitz et al., 1998. The teachings of each of the above disclosures are incorporated herein by reference. Antibodies that compete with any of these art-recognized antibodies for binding to CTLA-4 can also be used. For example, humanized CTLA-4 antibodies are described in International Patent Application Nos. WO2001 / 014424, WO2000 / 037504, and U.S. Patent No. 8,017,114; all of which are incorporated herein by reference.

[0213] Other anti-CTLA-4 antibodies that can be used as checkpoint inhibitors in the methods and compositions of the present disclosure are ipilimumab (also known as 10D1, MDX-010, MDX-101, and ) or antigen-binding fragments and variants thereof (see, e.g., WO01 / 14424).

[0214] In some embodiments, the inhibitor includes the heavy and light chain CDRs or VRs of tsimab or ipilimumab. Therefore, in one embodiment, the inhibitor includes the CDR1, CDR2, and CDR3 domains of the VH region of tsimab or ipilimumab, and the CDR1, CDR2, and CDR3 domains of the VL region of tsimab or ipilimumab. In another embodiment, the antibody competes with the above-mentioned antibodies for binding to the same epitope on PD-1, B7-1, or B7-2 and / or binds to the same epitope on PD-1, PD-L1, or B7-2. In another embodiment, the antibody has a variable region amino acid sequence identity of at least about 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% (or any range derivable therein) with the above-mentioned antibodies.

[0215] 2. Inhibition of co-stimulatory molecules

[0216] In some embodiments, immunotherapy includes inhibitors of costimulatory molecules. In some embodiments, inhibitors include B7-1 (CD80), B7-2 (CD86), CD28, ICOS, OX40 (TNFRSF4), 4-1BB (CD137; TNFRSF9), CD40L (CD40LG), GITR (TNFRSF18) inhibitors and combinations thereof. Inhibitors include inhibitory antibodies, polypeptides, compounds and nucleic acids.

[0217] 3. Dendritic cell therapy

[0218] Dendritic cell therapy stimulates an anti-tumor response by having dendritic cells present tumor antigens to lymphocytes, thereby activating dendritic cells, prompting them to kill other cells presenting the antigen. Dendritic cells are antigen presenting cells (APCs) in the mammalian immune system. In cancer treatment, they help target cancer antigens. An example of a dendritic cell-based cellular cancer therapy is Siplicept-T.

[0219] One way to induce dendritic cells to present tumor antigens is by inoculation with autologous tumor lysates or short peptides (a small portion of a protein corresponding to a protein antigen on cancer cells). These peptides are usually given in combination with adjuvants (highly immunogenic substances) to enhance immune and anti-tumor responses. Other adjuvants include proteins and other chemicals that attract and / or activate dendritic cells, such as macrophage colony stimulating factor (GM-CSF).

[0220] Dendritic cells can also be activated in vivo by causing tumor cells to express GM-CSF. This can be achieved by genetically engineering tumor cells to produce GM-CSF or by infecting tumor cells with an oncolytic virus that expresses GM-CSF.

[0221] Another strategy is to remove dendritic cells from the patient's blood and activate them in vitro. Dendritic cells are activated in the presence of tumor antigens, which can be a single tumor-specific peptide / protein or a tumor cell lysate (a solution of broken down tumor cells). These cells (and optional adjuvants) are injected and an immune response is stimulated.

[0222] Dendritic cell therapy involves the use of antibodies that bind to receptors on the surface of dendritic cells. Antigens can be added to the antibodies, and the antigens can induce the dendritic cells to mature and provide immunity to the tumor.

[0223] 4. CAR-T cell therapy

[0224] Chimeric antigen receptors (CARs, also called chimeric immunoreceptors, chimeric T-cell receptors, or artificial T-cell receptors) are engineered receptors that attach new specificities to immune cells to target cancer cells. Typically, these receptors graft the specificity of a monoclonal antibody onto a T cell. These receptors are called chimeras because they are made from a fusion of parts from different sources. CAR-T cell therapy refers to treatment using such transformed cells for cancer therapy.

[0225] The basic principle involved in CAR-T cells involves recombinant receptors that combine antigen binding and T cell activation functions. The general premise of CAR-T cells is to artificially create T cells that target markers found on cancer cells. Scientists can remove T cells from the human body, genetically modify them, and put them back into the patient to allow them to attack cancer cells. Once a T cell is engineered into a CAR-T cell, it acts as a "living drug." CAR-T cells establish a connection between an extracellular ligand recognition domain and an intracellular signaling molecule, thereby activating the T cell. The extracellular ligand recognition domain is usually a single-chain variable region fragment (scFv). An important aspect of the safety of CAR-T cell therapy is how to ensure that only cancerous tumor cells and not normal cells are targeted. The specificity of CAR-T cells is determined by the choice of the molecule being targeted.

[0226] Exemplary CAR-T therapies include Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta). In some embodiments, the CAR-T therapy targets CD19.

[0227] 5. Cytokine therapy

[0228] Cytokines are proteins produced by various cells present in tumors. They can modulate the immune response. Tumors often use them to grow and reduce the immune response. These immunomodulatory effects allow them to be used as drugs to induce immune responses. Two commonly used cytokines are interferons and interleukins.

[0229] Interferons are produced by the immune system. They are usually involved in antiviral responses, but are also used in cancer. They are divided into three groups: type I (IFNα and IFNβ), type II (IFNγ), and type III (IFNλ).

[0230] Interleukins have a range of immune system effects. IL-2 is an exemplary interleukin cytokine therapy.

[0231] 6. Adoptive T cell therapy

[0232] Adoptive T cell therapy is a form of passive immunity by infusing T cells (adoptive cell transfer). They are present in the blood and tissues and are usually activated when they find foreign pathogens. In particular, when the surface receptors of T cells encounter cells that display part of foreign proteins on their surface antigens, they will activate. These can be infected cells or antigen presenting cells (APC). They are present in normal tissues and tumor tissues, where they are called tumor infiltrating lymphocytes (TIL). They are activated in the presence of APCs such as dendritic cells that present tumor antigens. Although these cells can attack tumors, the environment within the tumor is highly immunosuppressive, preventing immune-mediated tumor death.

[0233] Various methods have been developed to produce and obtain tumor-targeted T cells. T cells directed against tumor antigens can be removed from tumor samples (TIL) or filtered from the blood. Subsequent activation and culture are then performed in vitro and the results are reinfused. Activation can be performed by gene therapy or by exposing T cells to tumor antigens.

[0234] It is contemplated that cancer treatment may exclude any cancer treatment described herein. Moreover, embodiments of the present disclosure include patients who have previously received a therapy described herein, patients who are currently receiving a therapy described herein, or patients who have not yet received a therapy described herein. In some embodiments, the patient is a patient who has been determined to be resistant to a therapy described herein. In some embodiments, the patient is a patient who has been determined to be sensitive to a therapy described herein.

[0235] B. Oncolytic viruses

[0236] In some embodiments, additional therapies include oncolytic viruses. Oncolytic viruses are viruses that preferentially infect and kill cancer cells. When infected cancer cells are destroyed by oncolysis, they release new infectious viral particles or virions to help destroy the remaining tumor. Oncolytic viruses are thought to not only directly destroy tumor cells, but also stimulate host anti-tumor immune responses for long-term immunotherapy.

[0237] C. Polysaccharide

[0238] In some embodiments, the additional therapy includes polysaccharides. Certain compounds found in mushrooms, primarily polysaccharides, can upregulate the immune system and can have anti-cancer properties. For example, beta-glucans such as lentinan have been shown to stimulate macrophages, NK cells, T cells, and immune system cytokines in laboratory studies and have been studied as immune adjuvants in clinical trials.

[0239] D. Neoantigens

[0240] In some embodiments, additional therapies include administering new antigens. Many tumors express mutations. These mutations may produce new targetable antigens (neoantigens) for T cell immunotherapy. The presence of CD8+T cells in cancer foci identified using RNA sequencing data is higher in tumors with high mutation loads. The levels of transcripts associated with the cytolytic activity of natural killer cells and T cells are positively correlated with the mutation load in many human tumors.

[0241] E. Chemotherapy

[0242] In some embodiments, the additional therapy comprises chemotherapy. Suitable chemotherapeutic agent classes include (a) alkylating agents, such as nitrogen mustards (e.g., dichloromethyldiethylamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil), ethyleneimine and methylmelamines (e.g., hexamethonium, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, chlorozoticin, streptozocin), and triazines (e.g., dicarbazine); (b) antimetabolites, such as folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., 5-fluorouracil, floxuridine, cytarabine, azathiocarbidine), and purine analogs and related materials (e.g., 6-mercaptopurine, 6-thioguanine, pentostatin); (c) natural products, vinca alkaloids (e.g., vinca alkaloids); (e.g., vinblastine, vincristine), epipodophyllotoxins (e.g., etoposide, teniposide), antibiotics (e.g., dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, and mitoxantrone), enzymes (e.g., L-asparaginase), and biological response modifiers (e.g., interferon-α); and (d) other agents, such as platinum ligands (e.g., cisplatin, carboplatin), substituted ureas (e.g., hydroxyurea), methylhydrazines (e.g., methylbenzylhydrazine), and adrenocortical inhibitors (e.g., paclitaxel and mitotane). In some embodiments, cisplatin is a particularly suitable chemotherapeutic agent.

[0243] Cisplatin is widely used to treat cancers such as metastatic testicular or ovarian cancer, advanced bladder cancer, head and neck cancer, cervical cancer, lung cancer or other tumors. Cisplatin cannot be absorbed orally and must therefore be delivered by other routes such as intravenous, subcutaneous, intratumoral or intraperitoneal injection. Cisplatin can be used alone or in combination with other agents. In certain embodiments, effective doses used in clinical applications include about 15 mg / m 5 days every three weeks. 2 About 20 mg / m 2 In some embodiments, the amount of cisplatin delivered to a cell and / or subject in combination with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding a therapeutic polypeptide is less than the amount delivered when cisplatin is used alone.

[0244] Other suitable chemotherapeutic agents include anti-microtubule agents such as paclitaxel and doxorubicin hydrochloride ("doxorubicin"). Combination therapy of the Egr-1 promoter / TNFα construct delivered by an adenoviral vector with doxorubicin was determined to be effective in overcoming resistance to chemotherapy and / or TNF-α, indicating that combination therapy of the construct and doxorubicin can overcome resistance to doxorubicin and TNF-α.

[0245] Doxorubicin is poorly absorbed and is preferably administered intravenously. In certain embodiments, a suitable intravenous dose for adults includes about 60 mg / m 2 Up to about 75 mg / m 2 , or about 25 mg / m2 per day every 2 or 3 consecutive days 2 To about 30mg / m 2 , repeated at intervals of about 3 to about 4 weeks, or about 20 mg / m once a week 2 Elderly patients should use the lowest dose when previous chemotherapy or neoplastic bone marrow involvement has resulted in previous myelosuppression or when the drug is used in combination with other myelosuppressive drugs.

[0246] Nitrogen mustards are another suitable chemotherapeutic agent useful in the methods of the present disclosure. Nitrogen mustards may include, but are not limited to, dichloromethyl diethylamine (HN2), cyclophosphamide and / or ifosfamide, melphalan (L-sarcolysin), and chlorambucil. Cyclophosphamide (Available from Mead Johnson), (available from Adria) is another suitable chemotherapeutic agent. Suitable oral dosages for adults include, for example, about 1 mg / kg / day to about 5 mg / kg / day, and intravenous dosages include, for example, initial divided doses of about 40 mg / kg to about 50 mg / kg for about 2 days to about 5 days, or about 10 mg / kg to about 15 mg / kg about every 7 days to about 10 days, or about 3 mg / kg to about 5 mg / kg twice a week, or about 1.5 mg / kg / day to about 3 mg / kg / day. Due to adverse gastrointestinal effects, intravenous routes are preferred. The drug can also sometimes be administered intramuscularly by infiltration or entry into a body cavity.

[0247] Other suitable chemotherapeutic agents include pyrimidine analogs such as cytarabine, 5-fluorouracil (fluorouracil; 5-FU) and floxuridine (fluorodeoxyuridine; FudR). 5-FU can be administered at about 7.5 mg / m 2 About 1000 mg / m 2 In addition, the 5-FU administration schedule can be various time periods, such as up to six weeks, or determined by a person of ordinary skill in the art to which the present disclosure belongs.

[0248] Another suitable chemotherapeutic agent is gemcitabine diphosphate ( Eli Lilly & Co., “gemcitabine”) is used to treat advanced and metastatic pancreatic cancer and therefore will also be used in the present disclosure for these cancers.

[0249] The amount of the chemotherapeutic agent delivered to the patient can be variable. In a suitable embodiment, when chemotherapy is applied together with the construct, the chemotherapeutic agent can be applied in an amount that effectively causes the cessation or regression of cancer in the host. In other embodiments, the chemotherapeutic agent can be applied in an amount of one-half to one-tenth of the chemotherapeutic effective dose of the chemotherapeutic agent. For example, the chemotherapeutic agent can be applied in an amount of about one-twentieth, about one-five-hundredth or even about one-five-thousandth of the chemotherapeutic effective dose of the chemotherapeutic agent. The desired therapeutic activity of the chemotherapeutic agent of the present disclosure combined with the construct can be tested in vivo, and the effective dose can be determined. For example, before testing in people, such compounds can be tested in a suitable animal model system, and suitable animal models include but are not limited to rats, mice, chickens, cattle, monkeys, rabbits, etc. In vitro testing can also be used to determine the suitable combination and dosage described in the present embodiment.

[0250] F. Radiation therapy

[0251] In some embodiments, the additional therapy or previous therapy includes radiation, such as ionizing radiation. As used herein, "ionizing radiation" refers to radiation that includes particles or photons that have sufficient energy or can generate sufficient energy through nuclear interactions to produce ionization (gain or loss of electrons). Exemplary and preferred ionizing radiation is x-radiation. Means for delivering x-radiation to target tissues or cells are well known in the art.

[0252] In some embodiments, the amount of ionizing radiation is greater than 20 Gy and is administered in one dose. In some embodiments, the amount of ionizing radiation is 18 Gy and is administered in three doses. In some embodiments, the amount of ionizing radiation is at least, at most, or exactly 2 Gy, 4 Gy, 6 Gy, 8 Gy, 10 Gy, 15 Gy, 16 Gy, 17 Gy, 18 Gy, 19 Gy, 20 Gy, 21 Gy, 22 Gy, 23 Gy, 24 Gy, 25 Gy, 26 Gy, 27 Gy, 18 Gy, 19 Gy, 30 Gy, 31 Gy, 32 Gy, 33 Gy, 34 Gy, 35 Gy, 36 Gy, 37 Gy, 38 Gy, 39 Gy, 40 Gy, 41 Gy, 42 Gy, 43 Gy, 44 Gy, 45 Gy, 46 Gy, 47 Gy, 48 Gy, 49 Gy, or 40 Gy (or any range derivable therein). In some embodiments, the ionizing radiation is administered in at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses (or any range derivable therein). If more than one dose is administered, the administration interval may be about 1 hour, 4 hours, 8 hours, 12 hours, or 24 hours, or 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days, or 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 12 weeks, 14 weeks, or 16 weeks, or any range derivable therein.

[0253] In some embodiments, the amount of IR can be expressed as a total dose of IR, which is then administered in fractionated doses. For example, in some embodiments, the total dose is 50 Gy, divided into 10 fractionated doses, each of which is 5 Gy. In some embodiments, the total dose is 50 Gy to 90 Gy, divided into 20 to 60 fractionated doses, each of which is 2-3 Gy. In some embodiments, the total dose of IR is at least, at most, or about 20 Gy, 21 Gy, 22 Gy, 23 Gy, 24 Gy, 25 Gy, 26 Gy, 27 Gy, 28 Gy, 29 Gy, 30 Gy, 31 Gy, 32 Gy, 33 Gy, 34 Gy, 35 Gy, 36 Gy, 37 Gy, 38 Gy, 39 Gy, 40, 41 Gy, 42 Gy, 43 Gy, 44 Gy, 45 Gy, 46 Gy, 47 Gy, 48 Gy, 49 Gy, 50 Gy, 51 Gy, 52 Gy, 53 Gy, 54 Gy, 55 Gy, 56 Gy, 57 Gy, 58 Gy, 59 Gy, 60 Gy, 61 Gy, 62 Gy, 63 Gy, 64 Gy, 65 Gy, 66 Gy, 67 Gy, 68 Gy, 69 Gy, 70 Gy, 71 Gy, 72 Gy, 73 Gy, 74 Gy, 75 Gy, 76 Gy, 77 Gy, 78 Gy, 79 Gy, 80 Gy, 5Gy, 46Gy, 47Gy, 48Gy, 49Gy, 50Gy, 51Gy, 52Gy, 53Gy, 54Gy, 55Gy, 56Gy, 57Gy, 58Gy, 59Gy, 60Gy, 61Gy, 62Gy, 63Gy, 64Gy, 65Gy, 66Gy, 67Gy, 68Gy, 69Gy, 70Gy, 71Gy, 72Gy, 73Gy, 74Gy , 75Gy, 76Gy, 77Gy, 78Gy, 79Gy, 80Gy, 81Gy, 82Gy, 83Gy, 84Gy, 85Gy, 86Gy, 87Gy, 88Gy, 89G y, 90Gy, 91Gy, 92Gy, 93Gy, 94Gy, 95Gy, 96Gy, 97Gy, 98Gy, 99Gy, 100Gy, 101Gy, 102Gy, 103G Gy, 130 Gy, 135 Gy, 140 Gy, or 150 Gy (or any range derivable therein). In some embodiments, the total dose is administered in fractionated doses of at least, at most, or about 1 Gy, 2 Gy, 3 Gy, 4 Gy, 5 Gy, 6 Gy, 7 Gy, 8 Gy, 9 Gy, 10 Gy, 12 Gy, 14 Gy, 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45, or 50 Gy (or any range derivable therein).In some embodiments, at least, at most, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 93, 94, 95, 96, 97, 98, 99, or 100 (or any range derivable therein) divided doses. In some embodiments, at least, at most, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 (or any range derivable therein) divided doses are administered daily. In some embodiments, at least, at most, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 (or any range derivable therein) divided doses are administered weekly.

[0254] G. Surgery

[0255] About 60% of cancer patients will undergo some type of surgery, including preventive, diagnostic or staging, therapeutic, and palliative surgery. Therapeutic surgery includes resection, in which all or part of the cancerous tissue is physically removed, excised, and / or destroyed, and may be used in conjunction with other therapies, such as the treatment of the present embodiment, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapy. Tumor resection refers to the physical removal of at least a portion of the tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microscope-controlled surgery (Mohs surgery).

[0256] After removal of some or all of the cancer cells, tissue or tumor, a cavity may be present in the body. Treatment can be accomplished by perfusing, injecting directly or applying topically to the area along with another anti-cancer treatment. This treatment can be repeated, for example, every 1, 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3, 4 and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. The dosages of these treatments can also vary.

[0257] H. Other reagents

[0258] It is expected that other reagents can be used in combination with certain aspects of this embodiment to improve the therapeutic effect of treatment. These other reagents include reagents that affect the upregulation of cell surface receptors and GAP connections, cell inhibitors and differentiation agents, cell adhesion inhibitors, reagents that increase the sensitivity of overproliferation cells to apoptosis inducing agents, or other biological reagents. Increasing intercellular signaling by increasing the number of GAP connections will increase the anti-overproliferation effect on neighboring overproliferation cell groups. In other embodiments, cell inhibitors or differentiation agents can be used in combination with certain aspects of this embodiment to improve the anti-overproliferation effect of treatment. It is considered that cell adhesion inhibitors are used to improve the efficacy of this embodiment. Examples of cell adhesion inhibitors are focal adhesion kinase (FAK) inhibitors and lovastatin (Lovastatin). It is also considered that other reagents that increase the sensitivity of overproliferation cells to apoptosis, such as antibody c225, can be used in combination with certain aspects of this embodiment to improve the therapeutic effect.

[0259] V. Combination Therapy

[0260] The compositions and related methods of the present disclosure, particularly administration of the masked therapeutic agents of the present disclosure, may also be used in conjunction with other therapies, such as those described herein or in conjunction with other conventional therapies known in the art for the treatment of cancer.

[0261] Therapeutic compositions and treatment disclosed herein can be carried out before, simultaneously and / or after another treatment or medicine, and the interval is several minutes to several weeks.In the embodiment that reagent is applied to cell, tissue or organism respectively, generally will ensure that there is no significant time period expiration between the time of each delivery, so that therapeutic agent will still be able to play a favorable joint action on cell, tissue or organism.For example, in this case, it is expected that cell, tissue or organism can be contacted with two, three, four or more than four reagents or treatments substantially simultaneously (that is, in less than about a few minutes). In other aspects, the administration of another therapeutic agent or treatment may be 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 ​​hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, 73 hours, 74 hours In some embodiments, one or more therapeutic agents or treatments may be administered or provided for a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks, or longer than 8 weeks, and any range derivable therein.

[0262] Various combinations of therapeutic agents and treatments can be employed. Non-limiting examples of such combinations are shown below, where a therapeutic agent, such as a composition disclosed herein, is "A" and a second agent, such as an additional agent or therapy described herein or known in the art, is "B".

[0263]

[0264] In some embodiments, more than one course of treatment may be employed. It is contemplated that multiple courses of treatment may be administered.

[0265] VI. Treatment Methods

[0266] The present methods and compositions relate to methods for treating cancer. In some embodiments, the cancer comprises a solid tumor. In some embodiments, the cancer is non-lymphoid. In some embodiments, the cancer is breast cancer or colon cancer.

[0267] The compositions of the present disclosure can be used for in vivo, in vitro or ex vivo administration. The route of administration of the composition can be, for example, intratumoral, intradermal, subcutaneous, intravenous, intralymphatic and intraperitoneal administration. In some embodiments, administration is intratumoral or intralymphatic or peri-tumoral. In some embodiments, the composition is directly administered to cancerous tissue or lymph nodes.

[0268] As used herein, "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer", "cancer", "cell proliferative disorder", "proliferative disorder" and "tumor" are not mutually exclusive herein.

[0269] Cancers suitable for treatment include, but are not limited to, tumors of all types, locations, sizes, and characteristics. The methods and compositions disclosed herein are suitable for treating, for example, pancreatic cancer, colon cancer, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphomas, anal cancer, appendix cancer, astrocytoma, childhood cerebellar or brain basal cell carcinoma, bile duct cancer, extrahepatic bladder cancer, bone cancer, osteosarcoma / malignant fibrous histiocytoma, brain stem glioma, brain tumor, cerebellar astrocytoma brain tumor, cerebral astrocytoma / malignant glioma brain tumor, ependymoma brain tumor, medulloblastoma brain tumor, supratentorial primitive neuroectodermal tumor brain tumor, visual pathway and hypothalamic glioma, breast cancer, specific breast cancers such as ductal carcinoma in situ, invasive ductal carcinoma, tubular breast carcinoma, medullary breast carcinoma, mucinous breast carcinoma, papillary breast carcinoma , cribriform breast cancer, invasive lobular carcinoma, inflammatory breast cancer, lobular carcinoma in situ, male breast cancer, Paget's disease of the nipple, phyllodes tumor of the breast, recurrent and / or metastatic breast cancer, cancer, luminal A or B breast cancer, triple-negative / basal-like breast cancer and HER2-enriched breast cancer, lymphoma, bronchial adenoma / carcinoid, tracheal cancer, Burkitt's lymphoma, carcinoid tumor, childhood carcinoid tumor, gastrointestinal cancer of unknown primary, central nervous system lymphoma, primary cerebellar astrocytoma, childhood brain astrocytoma / glioblastoma, childhood cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disease, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, Ependymoma, esophageal cancer, Ewing's disease, extragonadal germ cell tumors in children, extrahepatic bile duct cancer, eye cancer, retinoblastoma, gallbladder cancer, stomach (gastric) cancer, gastrointestinal carcinoid, gastrointestinal stromal tumors, germ cell tumors: extracranial, extragonadal, or ovarian, gestational trophoblastic tumors, brain stem gliomas, gliomas, cerebral astrocytomas in children, visual pathway and hypothalamic gliomas in children, gastric carcinoid, hairy cell leukemia, head and neck cancer, cardia cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway gliomas, intraocular melanoma in children, islet cell carcinoma (endocrine pancreas), Kaposi's sarcoma, kidney cancer (renal cell carcinoma), laryngeal cancer, leukemia, acute lymphoblastic leukemia (also known as lymphoblastic leukemia) cell leukemia), acute myeloid (also called acute myeloid leukemia) leukemia, chronic lymphocytic (also called chronic lymphocytic leukemia) leukemia, chronic myeloid (also called chronic myelogenous leukemia) leukemia, hairy cell lip cancer, oral cancer, liposarcoma, primary liver cancer,, non-small cell lung cancer, small cell lung cancer, lymphoma, AIDS-related lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma (old classification of all lymphomas except Hodgkin's lymphoma), primary central nervous system lymphoma, Waldenstrom's macroglobulinemia, malignant fibrous histiocytoma of bone / osteosarcoma, childhood medulloblastoma, intraocular (eye) melanoma, Merkel cell carcinoma,Malignant mesothelioma in adults, mesothelioma in children, metastatic squamous neck cancer, oral cancer, multiple endocrine neoplasia syndrome, multiple myeloma / plasmacytoma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative disorders, chronic myeloid leukemia, acute myeloid leukemia in adults, acute myeloid leukemia in children, multiple myeloma, chronic myeloproliferative disorders, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma / malignant, fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer (surface epithelial-stromal tumor), ovarian germ cell tumor, ovarian tumor of low malignant potential, pancreatic cancer, islet cell paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germ cell tumor, pineoblastoma, and supratentorial Primitive neuroectodermal tumors, childhood pituitary adenoma, plasmacytoma / multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, colorectal cancer, renal cell carcinoma (kidney cancer), transitional cell carcinoma of the renal pelvis and ureter, retinoblastoma, rhabdomyosarcoma, childhood salivary gland carcinosarcoma, Ewing's family of tumors, Kaposi's sarcoma, soft tissue sarcoma, uterine Sezary syndrome sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), skin cancer squamous neck cancer with occult primary, metastatic gastric cancer, supratentorial primitive neuroectodermal tumor, childhood T-cell lymphoma, testicular cancer, laryngeal cancer, thymoma, childhood thymoma, thymic cancer, thyroid cancer, urethral cancer, uterine cancer, endometrial sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, childhood vulvar cancer and Wilms tumor (kidney cancer).

[0270] VII. Pharmaceutical Compositions and Methods

[0271] In some embodiments, a pharmaceutical composition is administered to a subject. Various aspects relate to administering an effective amount of a composition to a subject. In some embodiments, a composition comprising an inhibitor can be administered to a subject or patient to treat cancer or reduce the size of a tumor. Additionally, these compounds can be administered in combination with other cancer therapies.

[0272] Compositions for parenteral administration can be formulated, for example, for injection by intravenous, catheter injection, intraarterial injection, intramuscular, subcutaneous or even intraperitoneal routes. Typically, such compositions can be prepared as injectable, liquid solutions or suspensions; they can also be prepared as solid forms suitable for adding liquids to prepare solutions or suspensions before injection; and the formulations can also be emulsified. According to the present disclosure, the preparation of such formulations is known to those skilled in the art. Other routes of administration include intratumoral, peritumoral, intralymphatic, injection into cancerous tissue, and injection into lymph nodes. In some embodiments, administration is systemic.

[0273] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations containing sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, it must be in a sterile form and must be fluid to a certain extent that it can be easily injected. It should also be stable under the conditions of manufacture and storage, and must be preserved under conditions that prevent the contaminating effects of microorganisms such as bacteria and fungi.

[0274] The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof and vegetable oils. Suitable fluidity can be maintained by, for example, using a coating such as lecithin, maintaining the required particle size in the case of a dispersion, and using a surfactant. Preventing microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents, such as sugar or sodium chloride. The lasting absorption of the injectable composition can be achieved by using an agent that delays absorption in the composition, such as aluminum monostearate and gelatin.

[0275] Sterile injectable solutions are prepared by combining the active compound in the desired amount with the various other ingredients listed above in an appropriate solvent, followed by sterilization by filtration if necessary. Typically, dispersions are prepared by incorporating the various sterile active ingredients into a sterile carrier containing a basic dispersion medium and other ingredients desired from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques, which produce powders of the active ingredient and any additional desired ingredients from pre-sterile filtered solutions thereof.

[0276] As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are suitable for contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problematic complications within the scope of sound medical judgment, and have a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or carrier involved in the delivery or transportation of a chemical agent, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material.

[0277] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali metal or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods.

[0278] Some variations in dosage will necessarily depend on the condition of the subject. In any case, the person responsible for administration will determine the dosage suitable for the individual subject. The effective amount of the therapeutic or preventive composition is determined based on the intended goal. The term "unit dose" or "dose" refers to a physically independent unit suitable for an object, each unit containing a predetermined amount of a composition, which is calculated to produce the desired response discussed above related to its administration (i.e., suitable route and regimen). The amount to be administered depends on the desired effect, depending on the number of treatments and the unit dose. The exact amount of the composition also depends on the physician's judgment and is unique to each person. Factors affecting dosage include the physical and clinical state of the subject, the route of administration, the intended goal of treatment (relief and cure of symptoms), and the efficacy, stability, and toxicity of the specific composition.

[0279] After formulation, the solution will be administered in a manner compatible with the dosage and in an amount effective for treatment or prevention. The preparation is easily administered in a variety of dosage forms, for example in the type of injectable solutions described above.

[0280] Typically, for an adult (weighing about 70 kg), about 0.1 mg to about 3000 mg (including all values ​​and ranges therebetween), or about 5 mg to about 1000 mg (including all values ​​and ranges therebetween), or about 10 mg to about 100 mg (including all values ​​and ranges therebetween) of the compound are administered. It should be understood that these dosage ranges are only by way of example, and administration can be adjusted according to factors known to the skilled person.

[0281] In some embodiments, about, at least about, or at most about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6 6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7 , 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 1 3.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 , 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 4, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 105, 110, 115, 12 0, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275,280、285、290、295、300、305、310、315、320、325、330、335、340、345、350、355、360、365、370、375、380、385、390、395、400、410、420、425、430、440、441、450、460、470、475、480、490、500、510、520、525、530、540、 550、560、570、575、580、590、600、610、620、625、630、640、650、660、670、675、680、690、700、710、720、725、730、740、750、760、770、775、780、790、800、810、820、825、830、840、850、860、870、875、880、890、900、 910、920、925、930、940、950、960、970、975、980、990、1000、1100、1200、1300、1400、1500、1600、1700、1800、1900、2000、2100、2200、2300、2400、2500、2600、2700、2800、2900、3000、3100、3200、3300、3400、350 0, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 6000, 7000, 8000, 9000, 10000 milligrams (mg) or micrograms (mcg) or μg / kg or micrograms / kg / minute or mg / kg / min or micrograms / kg / hour or mg / kg / hour, or any range derivable therein.

[0282] Can be administered as needed or every 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 18 hours or 24 hours (or any range derivable therein) or daily 1, 2, 3, 4, 5, 6, 7, 8, 9 times (or any range derivable therein). The dose can be first administered before or after the condition. In some embodiments, the first dose of the regimen can be administered to the patient 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours (or any range derivable therein) or 1 day, 2 days, 3 days, 4 days or 5 days (or any range derivable therein) after the patient experiences or exhibits signs or symptoms. The patient can be treated for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more than 10 days (or any range derivable therein) or until symptoms disappear or are alleviated or treatment is performed for 6 hours, 12 hours, 18 hours or 24 hours or 1 day, 2 days, 3 days, 4 days or 5 days after the disappearance or alleviation of the affected symptoms.

[0283] VIII. Examples

[0284] The following examples are included to illustrate preferred embodiments of the present disclosure. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques that the inventors have found to work well in the practice of the present disclosure, and therefore can be considered to establish preferred modes for its practice. However, based on the present disclosure, it will be appreciated by those skilled in the art that many changes may be made in the disclosed specific embodiments without departing from the spirit and scope of the present disclosure, and still similar or similar results may be obtained.

[0285] Example 1: Masked cytokines reduce toxicity and increase tumor-specific activation

[0286] Cytokine cancer immunotherapy using interleukin (IL)-12 has shown strong anti-tumor effects in both mice and humans. However, due to its severe toxicity, some IL12 clinical trials have been terminated or failed. To date, IL12 has not been approved for clinical use (1).

[0287] Immunotherapy is used to activate an immune response, and as such, side effects often result from drug action in healthy organs. One solution to overcome the toxicity problem is to prevent cytokine action in healthy tissues. One solution involves converting cytokines into prodrugs that are inactive in healthy tissues and during systemic circulation, but are locally activated at the site of disease. In antibody form, this concept has been developed as pro-antibodies (2). Recently, L12 has been developed to be fused to an anti-IL12 antibody to cover the IL12 receptor binding site, however, this approach involving antibody domains has not been shown to be successful in vivo (3). Described herein is a pro-cytokine (a prodrug in the form of a cytokine) comprising a masking agent and a cytokine connected by a substrate peptide that is cleaved by an enzyme such as a matrix metalloproteinase (MMP) present in the tumor microenvironment (tumor-associated protease cleavage site). MMPs are a family of proteases that are specifically activated in the tumor microenvironment to cleave their recognition sites. The pro-cytokines produced have been shown to be locally activated in the tumor microenvironment, providing an opportunity for tumor-targeted immunotherapy.

[0288] IL12 is a heterodimeric glycosylated cytokine consisting of disulfide-linked p35 (about 35 kDa) and p40 (about 40 kDa) subunits. It is secreted by activated antigen presenting cells (APCs) facing infection as an early proinflammatory cytokine. When bound to the IL12 receptor on CD4+T cells, IL12 promotes Th1 polarization and leads to IFNλ production (4). IL12 is considered an ideal anti-tumor therapeutic cytokine because it activates the innate and adaptive immunity of the immune system. Despite this, systemic administration of recombinant human IL12 (rh-IL12) has shown unsatisfactory results in clinical trials because of intolerable toxicity leading to the termination of trials of systemic IL12 administration (5). A major obstacle in recombinant IL12 therapy stems from the inability to achieve sufficiently high local concentrations within the tumor, thereby stimulating the development of tumor-targeted recombinant IL12 therapy to release the full therapeutic potential of this cytokine (1). Here, the inventors aim to develop a binding site masking method for IL12 to improve its toxicity. The present inventors have used the IL12 receptor β1 (IL12Rβ1) fibronectin I and II domains, which are the cytokine binding domains of this receptor protein, as a mask for the IL12 binding site.

[0289] The inventors have shown that chemical coupling of CBD protein to CPI and recombinant fusion to IL-2 improves anti-tumor effects compared to the unmodified form. The inventors combined this CBD technology with a pro-cytokine form; this combination provides for the extended presence of the masked pro-cytokine in the enzyme microenvironment to enhance the enzymatic masking of the pro-cytokine. This approach can also be applied to pro-antibodies.

[0290] A. Results

[0291] The inventors designed the fusion of IL12Rβ1 and IL12 protein using the first two fibronectin domains D1 and D2 of the receptor (Figure 1). The protein was expressed by HEK293 cells and then purified by histidine tag-affinity purification and size exclusion column.

[0292] To test the activity of IL12Rβ1-IL12, spleen cells were cultured in vitro for 2 days in the presence of IL12Rβ1-IL12. Compared with IL12, the fusion of IL12Rβ1 with IL12 (when IL12Rβ1 was fused to p35 and p40) significantly reduced the concentration of IFNγ, the main downstream molecule of IL12, in the culture medium, indicating that the fusion of IL12Rβ1 with IL12 reduced the activity of IL12 (Figure 2A). The inventors measured plasma IFNγ concentrations because IFNγ is the main downstream molecule of IL12 immunity and systemic IFNγ release causes systemic toxicity (Figure 2B). IL12 and its variants were injected into B16F10 tumor-bearing mice, and plasma was collected 2 days after injection, when IFNγ levels were highest according to previous experiments. In the absence of a protease cleavage sequence linking the IL12Rβ1 domain, IL12Rβ1-IL12 (in the context of IL12Rβ1 fused to p35 and p40) displayed undetectable IFNγ levels in plasma, whereas unmodified IL12 exhibited high IFNγ concentrations.

[0293] The inventors then expressed IL12Rβ1-IL12, which contained a protease cleavage site inserted between IL12Rβ1 and IL12. The inventors tested whether IL12Rβ1-VP-IL12 containing VPLSLYS (SEQ ID NO: 50) could be proteolytically cleaved by VPLSLYS (SEQ ID NO: 50) recognition enzymes MMP2 and MMP9 ( FIG. 3A ). SDS-PAGE analysis showed that MMP2 and MMP9 completely cleaved the IL12Rβ1 portion to produce IL12 heterodimers (about 60 kDa). Similarly, IL12Rβ1-LS-IL12 containing a LSGRSDNH (SEQ ID NO: 49) matrix was cleaved by uPA. As shown in FIG. 3A , these enzymes had no effect on IL12 itself.

[0294] Next, the inventors tested whether fusion of IL12Rβ1 with the p35 chain could reduce the biological activity of IL12 ( FIG. 3B ). As a proxy for the biological activity of IL12, the inventors measured STAT4 phosphorylation in response to different amounts of cytokines. The EC of unmodified IL12 50 The value was 16.3 pM, while the EC of proIL12 construct was 50The value was as low as about 80 times. To determine whether treatment of IL12Rβ1-VP-IL12 with MMP2 and IL12Rβ1-LS-IL12 with uPA could produce a functional response on T cells, the inventors compared the bioactivity of the cleaved and non-cleaved constructs with that of IL12 (Figure 3C). Consistent with previous results, STAT4 phosphorylation of the non-cleaved construct was reduced to about 80 times. However, treatment of the proIL12 construct with the respective proteases completely restored the bioactivity of IL12, showing a dose-response relationship similar to that of unmodified IL12.

[0295] To determine whether IL12Rβ1-VPLS-IL12-CBD also reduces toxicity in vivo, the inventors administered unmodified IL12 or increasing doses of IL12Rβ1-VPLS-IL12-CBD to healthy mice 3 times every 3 days ( Figure 3D). Two days after each injection, mice were bled and the presence of pro-inflammatory biomarkers in the serum was analyzed using LEGENDplex technology. The data indicate that IL12Rβ1-VPLS-IL12-CBD exhibits an enhanced safety profile compared to IL12. Importantly, 5μg IL12Rβ1-VPLS-IL12-CBD did not significantly upregulate any toxicity markers compared to PBS-treated mice, and 100μg IL12Rβ1-VPLS-IL12-CBD was generally better tolerated compared to IL12-treated mice. Thereafter, blood cell counts were measured in B16F10 tumor-bearing mice two days after IL12 injection. IL12 and CBD-IL12 induced a decrease in white blood cell counts in the blood, while all variants of IL12Rβ1-IL12 did not (Figure 3E). Platelet counts were maintained in all cases. These data indicate that the fusion of IL12Rβ1 to IL12 reduces systemic toxicity (Figure 3F). Blood toxicity markers were analyzed by biochemical analyzer 3 days after injection of IL12Rβ1-IL12 in non-tumor-bearing mice. When injected with 25 μg or 100 μg of IL12Rβ1-IL12, liver injury markers (blood albumin concentration, total protein, alanine aminotransferase (ALT) activity, aspartate aminotransferase (AST) activity, and alkaline phosphatase activity), kidney injury markers (total bilirubin), pancreatic injury markers (amylase), and lung injury markers (CO2 concentration) were comparable to those of the PBS-injected group (Figure 3G to N). Mice injected with 25 μg or 50 μg of IL12 showed a significant decrease in blood albumin concentration, and increased ALT activity, AST activity, total bilirubin, and amylase, indicating toxicity to several organs. When injected with 200 μg of IL12Rβ1-IL12, one of three mice responded with increased AST activity, total bilirubin, and amylase. These data suggest that the maximum tolerated dose of IL12Rβ1-IL12 is at least greater than 100 μg. When the inventors combined IL12Rβ1-IL1 with anti-PD-1 blocking antibodies, ALT activity and amylase levels were not significantly increased compared to wild-type IL12 therapy (Figure 3O to P).

[0296] The inventors then tested the anti-tumor effect of IL12 fused to IL12Rβ1 using the B16F10 model (Figure 4). IL12Rβ1-IL12 with uPA and thrombin cleavage sites showed anti-tumor effects. In contrast, IL12Rβ1-IL12 without a cleavable sequence did not show an anti-tumor effect (Figure 4B). These data indicate that IL12Rβ1-IL1 in tumors is activated by proteases and shows anti-tumor effects. Moreover, the anti-tumor effect of IL12Rβ1-IL12 containing CBD showed a higher anti-tumor effect than variants without CBD, indicating that the effect of CBD in prolonging the presence of procytokines in the enzymatic environment of the tumor increases its activity. The inventors also tested lower doses of IL12Rβ1-VPLS-IL12 and found that IL12Rβ1-VPLS-IL12 and IL12Rβ1-VPLS-IL12-CBD were as effective as IL12 (Figure 4C). The inventors next tested whether IL12Rβ1-IL12 with uPA and MMP cleavage sites synergized with anti-PD-1 blocking therapy (Figure 4D). Anti-PD-1 antibody therapy could not cure any B16F10 mice, but the combination of IL12Rβ1-LSHPVP-IL12 and anti-PD-1 antibody cured all 5 B16F10 tumors. As a result, we found that IL12Rβ1-IL12 increased the therapeutic effect of anti-PD-1 therapy.

[0297] B. Conclusion

[0298] Cytokines are key factors in anti-tumor activity, but not many of them have been translated into the clinic so far. IL12 is one of the strongest anti-tumor cytokines, but due to its high toxicity, clinical trials have been terminated or unsuccessful. Therefore, reducing its toxicity is an important strategy for its translation into the clinic. In order to improve CBD-IL12 therapy, the inventors fused the domain of the IL12 receptor IL12Rβ1 to IL12 to form IL12Rβ1-IL12. This fusion is inactive, but contains an MMP or thrombin cleavage site between the receptor mask and the cytokine, producing a pro-cytokine that can be activated in the tumor microenvironment. The inventors have demonstrated that the immunotoxicity of IL12 is thereby reduced, and that the fusion of IL12Rβ1-IL12 with a protease-sensitive linker maintains the therapeutic effect.

[0299] Because a single repeat of the MMP or thrombin cleavage site between the receptor masking and the cytokine produced an antitumor effect, we hypothesized that introducing multiple cleavage sites in the linker (e.g., tandem MMP, tandem thrombin, and MMP-thrombin dimers and repeats) would increase protease sensitivity and potentially increase the antitumor effect of IL12Rβ1-IL12 therapy.

[0300] In summary, this article describes the development of a technology to reduce cytokine toxicity by fusing cytokine receptors to cytokines. Tumor-specific proteases cleave the linker to activate the cytokine within the tumor.

[0301] C. Materials and Methods

[0302] 1. Production and purification of recombinant fusion proteins of VWF A3 domain, IL12Rβ1 and IL12

[0303] Protein production and purification were performed as previously described (7). Sequences encoding human VWF A3 domain residues Cys1670-Gly1874 (positions 907 to 1111 of mature VWF), mouse IL12, IL12Rβ1, and fusion proteins were synthesized and subcloned into the mammalian expression vector pcDNA3.1(+) by Genscript. A sequence encoding six His was added to the N-terminus for further purification of the recombinant protein. HEK-293F cells were routinely maintained in suspension in serum-free FreeStyle 293 Expression Medium (Gibco). On the day of transfection, cells were plated at 1 × 10 6 Cells were inoculated into fresh culture medium at a density of 10 cells / ml. 2 μg / ml plasmid DNA, 2 μg / ml linear 25 kDa polyethyleneimine (Polysciences) and OptiPRO SFM medium (final concentration 4%, Thermo Fisher) were added in sequence. The culture flask was shaken at 135 rpm at 37 °C in the presence of 5% CO2. Seven days after transfection, the cell culture medium was collected by centrifugation and filtered through a 0.22 μm filter. Use pure 25 (GE Healthcare) The culture medium is loaded into a HisTrap HP 5ml column (GE Healthcare). After washing the column with a wash buffer (20mM imidazole, 20mM NaH2PO4, 0.5M NaCl, pH 7.4), the protein is eluted with a gradient of 500mM imidazole (in 20mM NaH2PO4, 0.5M NaCl, pH 7.4). The eluate is further purified by size exclusion chromatography using a HiLoadSuperdex 200PG column (GE healthcare). All purification steps were performed at 4°C. The expression of the laminin LG domain was determined by immunoblotting using an anti-His tag antibody (Bio Legend), and the purity of the protein was confirmed to be >90% by SDS-PAGE.

[0304]

[0305]

[0306]

[0307] 2. Pro-IL12 cleavage assay

[0308] Recombinant mouse matrix metalloproteinase-2 (MMP2), MMP9 and recombinant human urokinase plasminogen activator (uPA) were purchased from R&D. Because MMP2 and MMP9 were provided in their zymogen form, MMPs were first activated using 1 mM p-aminophenylmercuric acetate (APMA, Sigma) for 2 hours at 37°C. After activation, MMPs and cytokines were diluted in a detection buffer containing 150 mM NaCl, 50 mMTris, 10 mM CaCl2, 0.05% Brij-35 at pH = 7.5. The final concentrations of MMP2, MMP9 and cytokines were 2 μg / mL, 5 μg / mL and 50 μg / mL, respectively. Cutting was performed at 37°C for 30 minutes. The samples were then analyzed by gel electrophoresis. Cutting using uPA was performed according to the manufacturer's protocol. The concentration of uPA was 10 μg / mL.

[0309] 3. In vitro stimulation assay

[0310] Using EasySep Mouse CD8 + T cell isolation kit (Stem Cell), purifying mouse CD8 T cells from the spleen of C57BL / 6 mice + Purified CD8 T cells were activated in six-well plates pre-coated with 2 μg / mL α-CD3 (clone 17A2, Bioxcell) and supplemented with soluble 5 μg / mL α-CD28 (clone 37.51, BioLegend) and 30 ng / mL mouse IL-2 (Peprotech). + T cells (10 6 cells / mL) for 3 days. The culture medium was IMDM (Gibco) containing 10% heat-inactivated FBS, 1% penicillin / streptomycin, and 50 μM 2-mercaptoethanol (Sigma Aldrich). After 3 days of culture, activated CD8 + T cells for 6 h and transferred to 96-well plates (50,000 cells / well). The indicated amounts of IL-12 or proIL12 variants were applied to CD8 +T cells for 20 minutes to induce STAT4 phosphorylation. Immediately fix the cells using BD Phosflow Lyse / Fix buffer at 37°C for 10 minutes and then permeabilize on ice using BD Phosflow Perm buffer III for 30 minutes. Cells were stained with Alexa Fluor (AF) 647-conjugated antibody that recognizes Tyr693 phosphorylation of anti-pSTAT4 (clone 38, BD). Stain for 1 hour at room temperature (RT) in the dark. Cells were acquired on a BD Fortessa X-20 and data were analyzed using FlowJo (Treestar). pSTAT4 was plotted + Plot of mean fluorescence intensity (MFI) of the population versus cytokine concentration. Dose-response curves were fitted using Prism (v8, GraphPad).

[0311] 4. Mice and Cell Lines

[0312] Mice and cell lines were prepared as described previously (8). C57BL / 6, 8 to 12 weeks old, were obtained from Charles River Laboratories. Experiments were performed with the approval of the Institutional Animal Care and Use Committee of the University of Chicago. B16F10 cells were obtained from the American Type Culture Collection and cultured according to the instructions. All cell lines were checked for mycoplasma contamination by the pathogen test IMPACT I (IDEXX BioResearch).

[0313] 5. Analysis of Plasma Cytokine Concentrations

[0314] Measurements were performed as described previously (8). 5 × 10 5 B16F10 melanoma cells. After 7 or 8 days, mice received 25 μg IL12 and equimolar IL12 variants. 100 μg anti-PD-1 antibody (clone: ​​29F.1A12, BioXCell) was injected intraperitoneally. Two days after IL12 injection, blood samples were collected in heparinized tubes containing EDTA and then centrifuged. Cytokine concentrations in plasma were measured by Ready-SET-Go! ELISA kits (eBioscience) or LEGENDplex kits (BioLegend) according to the manufacturer's protocol. LEGENDplex results were analyzed using the BD Fortessa X-20 flow cytometry system and FlowJo.

[0315] 6. Analysis of toxicity markers in serum

[0316] Nine-week-old C57BL / 6 mice were used. IL12 and IL12 variants were injected intravenously into the mice. Three days after the injection of IL12, blood samples were collected in tubes, followed by coagulation and centrifugation. Serum injury markers were measured by Vet Axcel (Alfa Wassermann) according to the manufacturer's protocol.

[0317] 7. Antitumor effect of IL12Rβ1-IL12 on B16F10 tumors

[0318] Measurements were performed as described previously (8). A total of 5 × 10 5 B16F10 cells were inoculated intradermally into the left side of the back of each C57BL / 6 mouse. After 7, 8 and / or 10 days, the mice were intravenously injected with IL12 (25 μg), IL12Rβ1-IL12 (equimolar, or 100 μg based on IL12) or CBD-IL12 (equimolar). 100 μg of anti-PD-1 antibody (clone: ​​29F.1A12, BioXCell) was injected intraperitoneally on days 7, 10 and / or 13. Tumors were measured with a digital caliper starting 8 days after tumor inoculation, and the volume was calculated as an ellipsoid, where V = 4 / 3×3.14×depth / 2×width / 2×height / 2. When the volume of any tumor exceeded 500mm 3 When , the mice were killed.

[0319] IX. Example 2 - Cytokine Implementation

[0320] The technique of covering the receptor binding site by fusing the cytokine receptor domain can be applied to other anti-tumor cytokines. This example teaches the fusion of receptors with IL-2 and IFNγ to produce other pro-cytokines, namely pro-IL-2 and pro-IFNγ. In all versions, MMP and / or thrombin responsive cleavage sites are inserted between the receptor and the cytokine. Exemplary embodiments of cytokines and masking agents are provided below:

[0321] Cytokines Masking Agent Human IL-2 Human IL-2Rα Human IL-2 Human IL-2Rβ Human IL-2 Human IL-2Rγ Mouse IL-2 Human IL-2Rα Mouse IL-2 Human IL-2Rβ Mouse IL-2 Human IL-2Rγ Human IFNγ Human IFNγR1 Human IFNγ Human IFNγR2 Mouse IFNγ Mouse IFNγR1 Mouse IFNγ Mouse IFNγR2

[0322] Example 3 - Addition of serum proteins for prolonged circulation.

[0323] Procytokines can be improved by CBD fusion to extend residence time in the tumor, and / or albumin fusion to extend circulation. Cytokines generally have a short half-life in the blood (9). Because procytokine technology generally relies on proteases in the body (i.e., the tumor), it is important to increase the residence time of the injected procytokine in the tumor. The inventors used two methods to improve the CND-cytokine platform. The first step is to fuse the collagen binding domain to the procytokine. As described in Example 1, due to the nature of the tumor vasculature, CBD can target and maintain the fused protein in the tumor. Therefore, the activity of the CBD-procytokine is more specific within the tumor, resulting in enhanced efficacy and safety. This is a dual tumor targeting system.

[0324] Another step is to extend the pro-cytokine blood half-life. Because the extended blood half-life of the injected cytokine will allow more opportunities to contact tumor tissue, it is hypothesized that the effect of the CBD-pro-cytokine will be further enhanced. This can be achieved by fusing albumin to the CBD-pro-cytokine or pro-cytokine. Therefore, these additional embodiments of tumor-targeted cytokines with extended blood half-lives that are active only within the tumor microenvironment are also contemplated.

[0325] *********

[0326] Although some embodiments have been described above with a certain degree of particularity or with reference to one or more than one separate embodiment, those skilled in the art may make various changes to the disclosed embodiments without departing from the scope of the present invention. In addition, where appropriate, aspects of any of the embodiments described above may be combined with aspects of any other embodiments described to form other embodiments having comparable or different performances and solving the same or different problems. Similarly, it should be understood that the above advantages and advantages may relate to one embodiment, or may relate to several embodiments. Any reference to a patent publication or other publication herein is a specific merger made by citing the disclosure of the publication. The claims should not be interpreted as including the limitation of method + function or step + function, unless the limitation is explicitly stated in a given claim using the expression "method for..." or "step for..."

[0327] References

[0328] The following references and publications are cited throughout the specification to the extent that they provide exemplary procedural or other details supplementary to those set forth herein and are expressly incorporated herein by reference.

[0329] 1. Kerkar, S.P., et al. IL12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. The Journal of clinical investigation 121, 4746 - 4757 (2011).

[0330] 2. Desnoyers, L.R., et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 5, 207ral44 (2013).

[0331] 3. Skrombolas, D., Sullivan, M. & Frelinger, J.G. Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 39, 233 - 245 (2019).

[0332] 4. Rogge, L., et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. The Journal of experimental medicine 185, 825 - 831 (1997).

[0333] 5. Lasek, W., Zagozdzon, R. & Jakobisiak, M. Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer immunology, immunotherapy: CII 63, 419 - 435 (2014).

[0334] 6. Ishihara, J., et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 11 (2019).

[0335] 7. Martino, M.M., et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 343, 885 - 888 (2014).

[0336] 8. Ishihara, J., et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med 9 (2017).

[0337] 9. Zhu, E.F., et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 21, 489 - 501 (2015)

Claims

1. Use of a polypeptide comprising IL12 linked to an IL12R polypeptide or fragment thereof by a linker in the preparation of a medicament for treating melanoma in a subject, wherein the IL12R polypeptide or fragment thereof specifically binds to IL12, the linker comprises one or more tumor-associated protease cleavage sites, the subject is undergoing immunotherapy, wherein the IL12R polypeptide or fragment thereof comprises L12Rβ1, and wherein the fibronectin domains D1 and D2 of IL12Rβ1 are linked to p35 and p40 of IL12 by a protease-cleavable linker.

2. The use according to claim 1, wherein the immunotherapy comprises an immune checkpoint inhibitor.

3. The use according to claim 2, wherein the immune checkpoint inhibitor comprises an anti-PD-1 monoclonal antibody or an anti-CTLA-4 monoclonal antibody.

4. The use according to claim 3, wherein the immune checkpoint inhibitor comprises one or more than one of nivolumab, pembrolizumab, pidilizumab, ipilimumab or tesimumab.

5. The use according to any one of claims 1 to 4, wherein the immunotherapy is administered before, after or simultaneously with the administration of the polypeptide.

6. The use according to any one of claims 1 to 4, wherein the polypeptide is administered systemically.

7. The use according to claim 6, wherein the polypeptide is administered by intravenous injection.

8. The use according to claim 1, wherein IL12 comprises p35 and p40 subunits linked by a disulfide bond.

9. The use according to claim 1, wherein IL12 comprises p35 and p40 subunits connected by a peptide linker.

10. The use according to any one of claims 1 to 4, wherein the IL12R polypeptide or fragment thereof is fused to the N-terminus of the p35 subunit of IL12, and wherein a linker is between the IL12R polypeptide or fragment thereof and the p35 subunit of IL12.

11. The use according to any one of claims 1 to 4, wherein the IL12R polypeptide or fragment thereof is fused to the C-terminus of the p40 subunit of IL12, and wherein a linker is between the IL12R polypeptide or fragment thereof and the p40 subunit of IL12.

12. The use according to any one of claims 1 to 4, wherein the polypeptide comprises at least two tumor-associated protease cleavage sites.

13. The use according to any one of claims 1 to 4, wherein the tumor-associated protease cleavage site comprises a uPA, a matrix metalloproteinase, or a thrombin cleavage site.

14. The use according to any one of claims 1 to 4, wherein the polypeptide is conjugated to a tumor targeting agent.

15. The use according to claim 14, wherein the tumor targeting agent comprises an antibody or an antigen-binding fragment thereof.

16. The use according to claim 15, wherein the antibody or antigen-binding fragment thereof comprises a matrix-targeted antibody or matrix-binding fragment thereof.

17. The use according to claim 16, wherein the antibody or antigen-binding fragment thereof specifically binds to fibronectin, an alternative splicing domain of fibronectin, collagen, tenascin, periostin, syndecan, proteoglycan or a tumor stromal cell-specific antigen.

18. The use according to claim 17, wherein the antibody or antigen-binding fragment thereof specifically binds to the Extra Domain A (EDA) or Extra Domain B (EDB) of fibronectin.

19. The use according to claim 17, wherein the tumor targeting agent comprises Fab that specifically binds to the alternative splicing domain of fibronectin comprising extra domain A (EDA).

20. The use according to claim 15, wherein the tumor targeting agent comprises an antibody or an antigen-binding fragment thereof that specifically binds to a tumor-associated antigen.

21. The use according to claim 14, wherein the tumor targeting agent comprises a collagen binding domain.

22. The use according to claim 21, wherein the polypeptide comprises at least two collagen binding domains.

23. The use of claim 21, wherein the polypeptide comprises a collagen binding domain from decorin or von Willebrand Factor (VWF).

24. The use according to any one of claims 1 to 4, wherein the polypeptide further comprises a serum protein conjugated to the polypeptide.

25. The use according to claim 24, wherein the serum protein is conjugated to the polypeptide via a peptide bond.

26. The use according to claim 24, wherein the serum protein comprises albumin.

27. The use according to any one of claims 1 to 4, wherein the polypeptide comprises a second linker.

28. The use according to claim 27, wherein the second linker comprises glycine and serine amino acid residues.

29. The use according to claim 28, wherein the linker comprises SEQ ID NO: 47 or SEQ ID NO:

48.

30. The use according to any one of claims 1 to 4, wherein the polypeptide comprises a protein tag.

31. The use according to any one of claims 1 to 4, wherein the polypeptide is not operably linked to a particle, nanovesicle or liposome.